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Synopsis
Discovery of a new drug often starts with screening large collection of compounds
against a certain biological target. These chemical libraries are typically very large,
on the order of hundreds of thousands, or even millions of compounds. Although new
technologies, such as High Throughput Screening (HTS) or Ultra High Throughput
Screening (UHTS), allow an assay of hundreds of thousand compounds per day, it
is still very expensive to screen the entire chemical library.
Therefore scientists have been trying to predict the activity of a compound by
using molecular properties as input variables. Based on the activity response and
the molecular properties on a sample, a quantitative structure activity relation-
ship (QSAR) model can be built and used to predict the activity of the remaining
compounds in the library. The most commonly used tools in QSAR are Linear
Regression and Partial Least Square. But these methods are simplification of the
real-world problems and do not perform well on heterogeneous datasets.
In this thesis, we propose several state-of-the-art algorithms from the machine
learning community to facilitate building QSAR models. These techniques have
good capability for generating complicated mathematical rules for classification,
vi
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prediction and recognition tasks without requiring much domain knowledge in many
fields. Our aim here is to evaluate the feasibility of introducing these machine
learning approaches to lead identification and its ADME/toxicity properties analysis.
Specifically, three machine learning methods, namely decision tree, k-nearest
neighbor and support vector machine , as well as preprocessing techniques such
as normalization and principal component analysis were explored. These methods
were tested on the inhibitor/antagonist prediction for the therapeutic targets— 5-
HT2 receptor and cholinesterase, and an ADME related target—CYP3A4.
The flow of work includes four steps. First of all, the examples of the in-
hibitors/antagonists of the three protein targets are collected manually from the
available references. Then the 3D structures of the compounds are encoded into
numerical vectors by QSAR molecular descriptors, which are analyzable by the ma-
chine learning techniques. After that, different machine learning models are derived
from the data sets. At the end, the prediction capacities of these models are evalu-
ated and analyzed.
The experimental results observed in all three data sets demonstrate that sup-
port vector machine beats decision tree and k-nearest neighbor and gives very good
results. It suggests that support vector machine may be a promising approach to
analyze the pharmaceutical properties of chemical compounds, which may lead to a
practical tool for drug design in the near future. Besides, principal component anal-
ysis also shows usefulness in dimensionality reduction, which, in general, improve
the prediction capacity, when used with support vector machine.
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Chapter 1
Introduction
1.1 Modern drug discovery and development
The drug discovery and development process is a sophisticated process (Figure 1.1).
It typically begins with target identification and validation. Target is usually an
enzyme, a receptor or an antibody associated with disease. Then different technolo-
gies such as chemical database screening and combinatorial chemistry are applied to
identify lead compounds (usually enzyme inhibitor or receptor agonist/antagonist),
which bind to the drug target to stop or alleviate disease. Preclinical tests on lead
compounds follow after, in order to select a few compounds with the best overall
profile on efficacy, absorption, distribution, metabolism, excretion, and toxicology.
The resulting compounds are filed as investigational new drugs (IND) with the FDA
(U.S. Food and Drug Administration), and are then carried into Phase I, Phase II,
and Phase III clinical trials. At the conclusion of successful preclinical and clinical
testing, a new drug application (NDA) is filed with the FDA. Nevertheless get-
ting the FDA approval is still not the end of the story. After that, pharmaceutical
companies may still need to conduct post-marketing studies.
On average, it requires an investment of US$880 million and as long as 10 ∼ 15
1
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Figure 1.1: Drug discovery and development procedure
years for an experimental drug to be approved by the FDA for marketing in the
United States[1]. About 75% of this cost (∼US$660 million) is attributable to failure
along the pharmaceutical value chain[1, 2]. Most compounds that are discovered and
undergone preclinical testing fail to meet the high safety and efficacy requirements
before testing in humans can proceed. Statistics shows that only five leads in 5,000
are able to enter human clinical testing. Furthermore, only one out of five drug
candidates approved for human clinical testing is ultimately approved for marketing.
To ensure that only those pharmaceutical products that are both safe and ef-
ficacious are brought to market, FDA and other relevant regulatory agencies have
imposed a very strict procedure for those pharmaceutical companies who apply for
permission to begin clinical testing on humans. Due to the high cost incurred from
these complicated and expensive protocols for the clinical and post-clinical processes,
pharmaceutical companies are paying more and more efforts on new technologies
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Figure 1.2: R&D Expenditures in Pharmaceutical Industry in U.S. and Abroad ,
1980–2001 ( Data Source:PhRMA annual survey 2001 )
pertaining to drug leads discovery and preclinical testing in order to improve the
quality of drug lead and reduce the failure rates throughout the pharmaceutical
value chain. Figure 1.2 shows the increasing trend of global R&D (research and de-
velopment) expenditures from 1980 to 2001 in pharmaceutical industry. Currently
nearly one-third of company financed R&D is devoted to the drug discovery phase
and the preclinical development. To innovate or to die has become the rule of thumb
of the game.
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1.2 Current lead identification and optimization
techniques
After studying the pathology of the diseased state and determining the target where
intervention is most likely to be effective, scientists can start looking for the possi-
ble lead compounds. Lead compound identification and optimization is considered
a bottle-neck in the whole drug discovery process. How to select lead candidates
which can be proven successful in preclinical and clinical trials is its challenging
objective. In the following subsections, the most widely used lead identification and
optimization methods were reviewed. However, the linear process of lead identi-
fication, evaluation and refinement activities is moving towards a more integrated
parallel process.
1.2.1 Lead identification
In the lead generation phase, compounds which can interact with the target protein
and modulate its activity are identified. Such compounds are mainly identified by
screening a chemical library. The prevailing approaches include high-throughput
screening, virtual screening and NMR screening as introduced below.
1.2.1.1 High-throughput screening
In the past five years, the technique of high-throughput screening (HTS), has gone
through a rapid development. Today, HTS for drug discovery has been established
in most pharmaceutical companies, and conducted in more than 500 laboratories
worldwide. An entire in–house compound libraries with millions of compounds can
be screened at a speed of 10,000 (HTS) to 100,000 compounds per day (uHTS,
ultra high–throughput screening) via very robust test assays[3, 4]. Combinatorial
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chemistry and parallel synthesis are employed to generate such huge numbers of
compounds.
However, there are some concerns regarding the “numbers’ game” . On one hand,
the largest chemical libraries available today include up to 10 million compounds
(107), while the chemical space consisted of carbon, oxygen, nitrogen, hydrogen,
sulfur, phosphorous, fluorine, chlorine and bromine, having a molecular weight of
less than 500 Da is estimated to cover 1062–1063 compounds[5]. Many potential drug
leads might be excluded from our investigation. On the other hand, as current com-
pound libraries are guided by simple chemistries, they are composed of compounds
that do not necessarily own “drug–like” attributes, such as target specificity, solu-
bility and oral bioavailability. Consequently even a compound is identified by HTS,
it might not always be suitable for initiation of further medicinal chemistry analysis.
1.2.1.2 Virtual screening
A different approach is in silico or virtual screening[6, 7]. With this computer
method, three–dimensional (3D) structures of compounds from virtual or physically
existing libraries are docked into binding sites of target proteins with known or pre-
dicted structures. Empirical scoring functions are used to evaluate the steric and
electrostatic complementarity (the fit) between the compounds and the target pro-
tein. The highest ranked compounds are then suggested for biological tests. Since
they do not require the compound entities and thus avoid expensive synthesis, these
software tools have drawn much attention after their debut in early 1980’s[8]. Fur-
thermore, they allow rapid and thorough understanding of the relationship between
chemical structure and biological function. It usually takes less than a minute to
screen a chemical structure when using the most elegant algorithms available today.
The throughput for a computer with 100 parallel CPUs is even higher compared to
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current uHTS technologies[6].
The main advantage of virtual screening is that it does not depend on the avail-
ability of compounds, meaning that not only in-house libraries, but also external or
virtual libraries can be searched. The application of scoring functions on the result-
ing data sets facilitate smart decision-making as to which chemical structures bear
the potential to exhibit the desired biological activity. However, one important pre-
requisite for these technologies is the availability of structure data of the target, and
if possible, in complex with the biological ligand or an effector molecule. Presently,
only about 1% of all highly annotated protein sequences have the experimental high
resolution structure information. Comparative models for more than 40% of these
proteins are available[9]. So, in silico screening can be applied on average to one
third and probably in the future to half of drug discovery projects.
1.2.1.3 NMR for lead identification
Traditionally nuclear magnetic resonance (NMR) was used only as an analytical
tool to aid chemists in characterizing small molecule compounds. Today, due to the
rapid development and wide application of X-ray crystallography and NMR to de-
termine atomic-resolution structures of proteins, nucleic acids, and their complexes,
NMR has been established as a key method in structure-based drug design. It has
the unique advantage of being able to detect and quantify interactions with high
sensitivity without requiring prior knowledge of protein function. Moreover, NMR
can provide structural information on both the target and the ligand to aid sub-
sequent optimization of weak–binding hits into high–affinity leads. More about its
application in drug discovery can be found in NMR in Drug Discovery [10].
Once hits (compounds that elicit a positive response in a particular biological
assay) have been identified by applying the different screening approaches, they
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will be validated by re–testing them and checking the purity and structure of the
compounds. This is to avoid wasting time with further characterizations of false
positive compounds from the screening. Only when the hits fulfill certain criteria
will these be regarded as leads. The criteria are developed from different aspects
such as:
• pharmacodynamic properties: efficacy, potency and selectivity in vitro and in
vivo;
• physicochemical properties: e.g., Lipinski’s “rule–of–five”1, water–solubility
and chemical stability;
• pharmacokinetic properties: e.g., permeability in the Caco–2 assay;
• chemical optimization potential: the difficulty of chemical synthesis can be cru-
cial, “dead–end–leads” which are synthetically not easily amendable to many
variations should be avoided;
• patentability: compounds that are to some extent protected by competitor’s
patents are certainly less interesting than entirely new lead structures.
1.2.2 Lead optimization
During the lead optimization phase, small organic molecules are chemically modi-
fied and pharmacologically characterized in order to obtain compounds with suitable
1Christopher Lipinski, established a set of rules, known throughout the drug discovery world
simply as the Rule of Five. Although there are only four rules, each rule involves a multiple of five
as a parameter. Lipinski’s Rule of Five has become a touchstone for drug researchers to predict
which compounds are most drug-like and thus the best potential candidates. According to these
rules, poor absorption is likely when several of the following occur: (1)There are more than 5
hydrogen bond donors; (2)There are more than 10 hydrogen bond acceptors; (3)The molecular
weight is over 500; (4)The ClogP is over 5.
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pharmacodynamic and pharmacokinetic properties to become a drug. This process
ideally requires the simultaneous optimization of multiple parameters and thus is
a time-consuming and costly step, which probably constitutes the “tightest” bot-
tleneck in drug discovery. However, by turning a biologically active chemical into
an effective and safe drug, lead optimization contributes essentially towards added
value in the drug discovery chain.
Lead optimization generally involves iterative rounds of synthetic organic chem-
istry and compound evaluation that can take from months to years of time and
involve the efforts of a team of synthetic organic chemists. The starting point is the
collection and analysis of structure-activity relationship (SAR) data. Initial SAR
data can be obtained from commercial sources. The first synthetic efforts will gen-
erally focus on systematic exploration of tolerated candidate molecule. Later rounds
will build the initial analysis and are often targeted at solving particular problems.
One important goal of compound optimization is to improve potency, since high
potency minimizes dose and hence improves specificity and reduces toxicity. Po-
tencies (expressed as EC50) in the range of 100 nM or higher are desired, though
much lower potency can be tolerated given high specificity, low toxicity, and the
administration mode that can accommodate the required dose.
Several approaches are available to maximize the utility of SAR information
for directed acquisition and synthesis of structural analogs to improve compound
potency. Advice from experienced medicinal chemists is of considerable practical
value to identify undesirable structural features that may result in failure because
of toxicity, poor biological stability, immunogenicity, or mutagenic potential[11].
Consideration of empirical information about drug successes and failures can be
quite helpful in directing synthesis efforts.
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At present, three major computational methods have been used in lead optimiza-
tion: rational structural design, pharmacophore analysis, and quantitative structure-
activity relationship (QSAR) analysis. These three may be used individually or in
combination.
Rational design methods generally use a high-resolution structure of the target
to direct the synthesis of new analogs. The process often involves generating of a
very large in silico library of potential derivatives and use of computational docking
methods to select derivatives that may interact with the target on the basis of shape
complementarities and charge placement. While intellectually appealing, there have
been few successful examples from application of this strategy alone.
Pharmacophore methods involve definition of the minimal unit that leads to
activity (usually a combination of hydrogen bond donor/acceptors, hydrophobic
groups, and other functional groups) in a three-dimensional space[12, 13, 14, 15].
The consensus pharmacophore is then used to examine the allowed placement of
groups in a set of candidate compounds. Pharmacophore analysis can be carried
out without structural information and is most useful in identifying new compounds
with a desired activity based on a three-dimensional similarity to early leads. Inter-
estingly, the structures of many of the novel cystic fibrosis transmembrane conduc-
tance regulator (CFTR) activators identified by HTS fit well in the flavone-based
pharmacophore model, suggesting a common binding site[16].
The last approach is to establish QSAR models that relate calculated physico-
chemical properties of molecules, rather than strictly structural characteristics, to
activity[17, 18]. This type of modelling is particularly important in directing mod-
ifications to pharmacokinetic and pharmacodynamic parameters. QSAR modelling
requires a set of structurally related compounds with a wide range of activities, ide-
ally 1,000-fold variation in activity, which is often a difficult requirement to meet.
1.2 Current lead identification and optimization techniques 10
1.2.3 ADME and toxicity properties of lead compounds
The three major reasons a drug fails during clinical trials are lack of efficacy, unac-
ceptable adverse effects, and unfavorable absorption, distribution, metabolism, and
excretion (ADME) properties. Therefore, the ultimate success of a compound is not
only defined by its biological activity and potency, but also its ADME/toxicity
properties. Although high-throughput screening has substantially increased the
number of lead compounds, most of these compounds are eliminated during ad-
ditional screening and testing. Of the drug candidates that enter the clinical de-
velopment phase, more than 40% fail to reach the market because of unfavorable
drug metabolism and pharmacokinetic properties, with an additional 11% elimi-
nated because of toxicity[19, 20, 21]. Therefore, it would be desirable to predict
ADME properties of the drug lead in early stage of drug development. Based on a
“fail fast, fail cheap” philosophy, ADME and toxicity tests of lead compounds have
been moved forward from preclinical trial to lead optimization phase, or even lead
identification phase.
High-throughput screening technology has allowed a dramatic increase in the
number of lead compounds, whereas technologies used in developing screens for
pharmacokinetic properties have lagged behind. Nowadays, the fastest methods in
use for ADME screening are several orders of magnitude slower than those for lead
identification. Sometimes, when the data size is not that big, medicinal chemists
may use liquid chromatography–mass spectrometry (LC–MS) techniques. From the
long time experience, many medicinal chemists have also come up with some “com-
mon sense” to facilitate the judgement of the ADME/toxicity properties of some
compounds.
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1.3 Inhibitor/antagonist — a plentiful source of
drug leads
Previous study shows that drugs act via the interaction with mainly two type of
proteins—enzymes and receptors[22]. According to TTD–the therapeutic target
database(TTD)2[23], enzymes contribute to 44% of the total drug targets and re-
ceptors covers 33%.
Figure 1.3: Biochemical classes of drug targets in TTD
Enzyme inhibition represents a major strategy in drug design and almost one-
third of the current top fifty drugs by sales are enzyme inhibitors. The inhibition
of an enzyme-catalyzed reaction will enable the selective modulation of a variety of
2It is a comprehensive database providing information about the known and explored therapeu-
tic protein and nucleic acid targets, the targeted disease, pathway information and the correspond-
ing drugs/ligands directed at each of these targets. This database currently contains information
about 125 different diseases/condistions, 1174 targets and 1251 drugs/ligands. It is available at
http://xin.cz3.nus.edu.sg for free non-commercial use.
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biochemical processes such as making cell growth, division and viability untenable,
or interrupting major metabolic pathways by blocking the formation of an essential
or undesirable metabolite.
Figure 1.4: Complementarity between enzyme inhibition and receptor antagonism
Receptor modulation via antagonist is complementary to enzyme inhibition. As
shown in Figure 1.4, the biological activity of species “B” can be attenuated via
inhibition of the enzyme involved in its biosynthesis. The same overall effect can
also be achieved via antagonism of the receptor(s) for “B”. A good example of this
is the attenuation of the action of the vasoconstrictor peptide angiotensin II (AII),
which can be achieved via inhibition of its biosynthesis by the angiotensin converting
enzyme (ACE) inhibitor or via AII receptor antagonism.
There are a number of successful drugs that were developed from inhibitors/antagonists.
For example, angiotensin II receptor antagonists are currently approved for the treat-
ment of hypertension. Various antipsychotic agents and antidepressants bind with
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relatively high affinity at 5-HT2A receptors as antagonists. And most new anti-AIDS
agents are HIV protease inhibitors.
Another point that should not be ignored is in many cases, few drugs interact
only with their intended targets. Most drug molecules can combine with not only
their main therapeutic target, but also other enzymes, receptors or other biological
entities. This is also a major cause of adverse drug reaction.
Therefore inhibitor identification for many targets are of great significance. Not
only may it lead to potential novel drug leads, but also it may provide insights to
the mechanism of toxicology/ADME profile of these molecules. Scientists are paying
increasingly more efforts to find new inhibitors which may have less side effects and
no or little resistance for many diseases.
1.4 Thesis outlines
New drugs are constantly required to combat drug resistance, even though it can
be minimized by the correct use of medicines by patients. They are also required
to improve the treatment of existing diseases, to treat newly identified diseases and
to produce safer drugs with no or minimal adverse side effects. To this end, new
efficient techniques for drug design which are able to help us develop high-quality
drugs at lower cost and in shorter development period are urgently needed.
In this thesis, I have tried to establish a work flow to predict the possibility
of a compound to become a potential drug based on its potential to inhibit (or
antagonize) the target protein, as well as its potential to inhibit ADME/toxicity
related proteins using a series of widely used machine learning techniques.
This is an in silico method which is based on previous pharmaceutical knowledge
and information, and thus a large number of expensive and labor-concentrated assays
can be saved. More importantly, compared with other modelling methods, this
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method is independent of the structure of target protein. So it is particularly useful
when the high-resolution 3D structure of the target protein is not available or when
the target undergoes big conformational changes during target-ligand interaction.
Specifically, I have worked on the inhibitor prediction of the receptor target—
5-HT2, the enzyme target—cholinesterase and the ADME related target—CYP3A4
using different machine learning approaches. Results suggest that support vector
machine (SVM) outperforms other methods and shows promising application po-
tential to drug discovery.
This thesis consists of six chapters:
Chapter 2 illustrates the framework of how we apply state-of-art machine learning
techniques to the field of drug discovery. Many technical details are introduced, such
as feature vector construction, pharmaceutical data preprocessing, machine learning
algorithms, and performance analysis and evaluation. In Chapter 3, Chapter 4
and Chapter 5, these techniques are tested on three typical inhibitor/antagonist
prediction scenarios. Finally Chapter 6 concludes the thesis.
Chapter 2
Practical implementation of machine
learning screening
2.1 Motivation
As discussed in Chapter 1, two most important goals in drug design are to find
active compounds in large databases quickly and to obtain an interpretable model for
what properties make a specific subset of compounds active. Taking the economics
of pharmaceutical industry into consideration, drug discovery is really an exciting
field full of uncertainty and challenges. It is drawing more and more attention of
scientists and researchers in both academia and industry.
Recently machine learning approaches have been introduced to address drug de-
sign problems, which have shown intriguing successes. For example, some machine
learning techniques have been successfully applied to the problem of SAR analysis.
Thomas M. Frimurer and his co-workers used artificial neural network to discrimi-
nate potential drug-like molecules from large compound databases in 2000[24]. They
found that this method gives much better prediction than the widely used “Rule of
Five”. Markus Wagener and his co-workers developed a model of decision tree to
15
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Figure 2.1: Flow chart of machine learning screening
discriminate between potential drugs and nondrugs[25]. Besides acceptable predic-
tion accuracy, they have delivered some comprehensible rules to explain the most
significant differences between drugs and nondrugs.
In this work, I furthered their study of identifying the drug-like chemical com-
pounds to the identification of potential drug leads for a particular disease. Specif-
ically I have worked on the inhibitor/antagonist prediction for three particular pro-
tein targets of pharmacological significance using three representatives of different
machine learning algorithms. The aim is to evaluate the feasibility of introducing
machine learning approaches to lead identification and toxicity/ADME properties
analysis.
The flow chart of my work is shown in Figure 2.1. First the examples of the
inhibitors/antagonist of a certain protein target need to be collected from different
reference sources. Then, these data of 3D structures of compounds need to be
transformed into a numerical vectors recognizable by machine leaning techniques.
After that a machine learning model is derived from the data sets. Finally, the
prediction capacities of these models are evaluated. In the remaining of this chapter,
three main technical problems regarding the implementation of the machine learning
screening I have used are addressed in detail.
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2.2 Feature vector construction
The data we have collected are the 3D structures of those inhibitor and non-inhibitor
compounds. But most machine learning algorithms cannot accept the chemical
structures directly. In order to use different machine learning algorithms to build
classifiers, we have to transform the structure information of these compounds into
feature vector information of homogeneous length. In SAR or QSAR analysis, molec-
ular descriptors are widely used to represent a wealth of information implicitly en-
coded in the 2D- and 3D- structures of chemical compounds, such as molecular
weight, atom type distribution, polarizability index etc. In this study, a total of 159
molecular descriptors are calculated for all positive and negative examples, which
includes 14 simple descriptors, 116 topological descriptors, 13 quantum chemical
descriptors and 16 geometrical descriptors. The full list of the 159 descriptors could
be found in Table 2.1.
Table 2.1: The full list of 159 descriptors
No. Name Description Reference
Simple descriptors (14 parameters)
1 Wmol Molecular weight
2 Nhyd Count of hydrogen atoms
3 Nhal Count of halogen atoms
4 Nhet Count of hetero atoms
5 Nhea Count of heavy atoms
6 NF Count of F atoms
7 NCl Count of Cl atoms
8 NBr Count of Br atoms
9 NI Count of I atoms
10 NC Count of C atoms
11 NP Count of P atoms
12 NS Count of S atoms
13 NO Count of O atoms
14 NN Count of N atoms
Topological descriptors (116 parameters)
15 Nring Numbers of rings
16 Nrot Number of rotatable bonds
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No. Name Description Reference
17 Ndonr Number of H-bond donors
18 Naccr Number of H-bond acceptors
19– 0χ,1 χ, Simple molecular connectivity Chi indices for path order 0-2 [26, 27]
21 2χ
22 3χp Simple molecular connectivity Chi indices for path order 3
23 3χc Simple molecular connectivity Chi indices for cluster
24 4χpc Simple molecular connectivity Chi indices for path/cluster
25 3χCH Simple molecular connectivity Chi indices
– 4χCH for cycles of 3, 4, 5, and 6 atoms
28 5χCH
6χCH
29- 0χpi,1 χpi Valence molecular connectivity Chi indices for path order 0-2
31 2χpi
32 3χpip Valence molecular connectivity Chi indices for path order 3
33 3χpic Valence molecular connectivity Chi indices for cluster
34 3χpipc Valence molecular connectivity Chi indices for path/cluster
35 3χpiCH valence molecular connectivity Chi indices for cycles
– 4χpiCH of 3, 4, 5, and 6 atoms
38 5χpiCH
6χpiCH
39 1k Molecular shape Kappa indices for one-three boned fragments [26]
– 2k
41 3k
42 1kα Kappa alpha indices for one-three boned fragments
– 2kα
44 3kα
45 phi Kier molecular flexibility index
46 0k Zero order Kappa index
47 Shev Sum of electrotopological state (Estate) indices of heavy atoms [28, 29]
48 Scar Sum of Estate indices of carbon atoms [30, 31]
49 Shet Sum of Estate indices of hetero atoms
50 Shal Sum of Estate indices of halogen atoms
51 S(1) Atom-type H Estate sum for -OH
52 S(2) Atom-type H Estate sum for =NH
53 S(3) Atom-type H Estate sum for -SH
54 S(4) Atom-type H Estate sum for −NH2
55 S(5) Atom-type H Estate sum for >NH
56 S(6) Atom-type H Estate sum for : NH:
57 S(7) Atom-type H Estate sum for ]CH(sp)
58 S(8) Atom-type H Estate sum for = CH2(sp2)
59 S(9) Atom-type H Estate sum for =CH–(sp2)
60 S(10) Atom-type H Estate sum for :CH:(sp2, aromatic)
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No. Name Description Reference
61 S(11) Atom-type H Estate sum for CHnX(sp3, X = F,Cl,Br, I)
62 S(12) Atom-type H Estate sum for CHn (Saturated) [27-30]
63 S(13) Atom-type H Estate sum for CHn (unsaturated)
64 S(14) Atom-type H Estate sum for CHn (aromatic)
65 S(15) Atom-type H Estate sum for AHn (not C, N, O, S)
66 S(16) Atom-type Estate sum for –CH3
67 S(17) Atom-type Estate sum for =CH2
68 S(18) Atom-type Estate sum for >CH2
69 S(19) Atom-type Estate sum for ≡CH
70 S(20) Atom-type Estate sum for =CH-
71 S(21) Atom-type Estate sum for : CH : (aromatic)
72 S(22) Atom-type Estate sum for >CH-
73 S(23) Atom-type Estate sum for =C=
74 S(24) Atom-type Estate sum for ≡C-
75 S(25) Atom-type Estate sum for =C<
76 S(26) Atom-type Estate sum for : C:-
77 S(27) Atom-type Estate sum for : C ::
78 S(28) Atom-type Estate sum for >C<
79 S(29) Atom-type Estate sum for -NH2
80 S(30) Atom-type Estate sum for =NH
81 S(31) Atom-type Estate sum for >NH
82 S(32) Atom-type Estate sum for :NH:
83 S(33) Atom-type Estate sum for ≡N
84 S(34) Atom-type Estate sum for =N-
85 S(35) Atom-type Estate sum for :N:
86 S(36) Atom-type Estate sum for >N-
87 S(37) Atom-type Estate sum for -N<< (NO2)
88 S(38) Atom-type Estate sum for :N:-
89 S(39) Atom-type Estate sum for -OH
90 S(40) Atom-type Estate sum for =O
91 S(41) Atom-type Estate sum for -O-
92 S(42) Atom-type Estate sum for :O:
93 S(43) Atom-type Estate sum for -F
94 S(44) Atom-type Estate sum for -SiH3
95 S(45) Atom-type Estate sum for -SiH2-
96 S(46) Atom-type Estate sum for >SiH-
97 S(47) Atom-type Estate sum for >Si<
98 S(48) Atom-type Estate sum for -PH2
99 S(49) Atom-type Estate sum for -PH-
100 S(50) Atom-type Estate sum for >P-
101 S(51) Atom-type Estate sum for →P=(P.O)
102 S(52) Atom-type Estate sum for -=P=(P.O2)
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No. Name Description Reference
103 S(53) Atom-type Estate sum for =PH3
104 S(54) Atom-type Estate sum for -SH [27-30]
105 S(55) Atom-type Estate sum for =S
106 S(56) Atom-type Estate sum for -S-
107 S(57) Atom-type Estate sum for :S:
108 S(58) Atom-type Estate sum for >S=O
109 S(59) Atom-type Estate sum for >S<<
110 S(60) Atom-type Estate sum for -Cl
111 S(61) Atom-type Estate sum for GeH3
112 S(62) Atom-type Estate sum for -GeH2-
113 S(63) Atom-type Estate sum for >GeH-
114 S(64) Atom-type Estate sum for >Ge<
115 S(65) Atom-type Estate sum for -AsH2
116 S(66) Atom-type Estate sum for -AsH-
117 S(67) Atom-type Estate sum for >As-
118 S(68) Atom-type Estate sum for →As=
119 S(69) Atom-type Estate sum for -SeH
120 S(70) Atom-type Estate sum for =Se
121 S(71) Atom-type Estate sum for -Se-
122 S(72) Atom-type Estate sum for :Se:
123 S(73) Atom-type Estate sum for >Se=
124 S(74) Atom-type Estate sum for -=Se=-
125 S(75) Atom-type Estate sum for -Br
126 S(76) Atom-type Estate sum for -SnH3
127 S(77) Atom-type Estate sum for -SnH2-
128 S(78) Atom-type Estate sum for >SnH-
129 S(79) Atom-type Estate sum for >Sn<
130 S(80) Atom-type Estate sum for -I
Quantum chemical descriptors (13 parameters)
131 pii Polarizability index [32, 33]
132 εa Hydrogen bond donor acidity (covalent HBDA)
133 εb Hydrogen bond acceptor basicity (covalent HBAB)
134 q+ Atomic charge on the most positively charged H atom
135 q− Largest negative charge on an non-H atom
136 µ Molecular dipole moment
137 η Absolute hardness [34, 35]
138 SN Softness
139 IP Ionization potential
140 A Electron affinity
141 µcp Chemical potential
142 χen Electronegativity index
143 ω Electrophilicity index
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No. Name Description Reference
Geometric descriptors (16 parameters)
144 dis1 Length vectors (longest distance, longest third atom, 4th atom)
– dis2
146 dis3
147 Vmc Van der Waals molecular volume
148 AS Solvent accessible surface area [36]
149 VS van der Waals surface area
150 MS Molecular surface area
151 PSA Polar molecular surface area
152 Sapc Sum of solvent accessible surface areas of positively charged atoms
153 Sanc Sum of solvent accessible surface areas of negatively charged atoms
154 Sapcw Sum of charge weighted solvent accessible surface areas of posi-
tively charged atoms
155 Sancw Sum of charge weighted solvent accessible surface areas of nega-
tively charged atoms
156 Svpc Sum of van der Waals surface areas of positively charged atoms
157 Svnc Sum of van der Waals surface areas of negatively charged atoms
158 Svpcw Sum of charge weighted van der Waals surface areas of positively
charged atoms
159 Svncw Sum of charge weighted van der Waals surface areas of negatively
charged atoms
2.3 Data preprocessing
While neglected by many machine learning researchers in the area of bioinformatics,
preprocessing is regarded as a crucial step for serious real world data mining by
the machine learning community. Normally the preprocessing steps include data
cleaning (such as management of missing values and replicate handling), normal-
ization, feature selection and et al. After these steps, the processed data sets can
be sent to various machine learning tools. The data cleaning will be addressed case
by case in following chapters, together with data collection. Here, in this section,
normalization and feature selection are discussed.
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2.3.1 Normalization
In the application of drug design, the range of features values differ a lot, such as
the value of “molecular weight” (the first descriptor in Table 3.1) is hundreds or
even thousands greater than “Valence molecular connectivity χ indices for cluster”
(the 33th descriptor whose range is in [0, 5] in Table 3.1). Thus “molecular weight”
might overpower the “Valence molecular connectivity χ indices for cluster” when
the data sets are sent to principal component analysis and distance-based classifier
like knn though the facts should not be that. Normalization or scaling is a widely
used preprocessing technique for this dilemma. Scaling data values in a range such
as [0, 1] or [−1, 1] prevents features with large range outweighing over features with
smaller range. Besides scaling may improve the accuracy and efficiency of compu-
tation involving distance multiplication or division operations. In this work, the
same normalization scheme is adopted as by LIBSVM[37], a famous support vector
machine classification toolbox.
Anewi =
2{Ai − [max(Ai)−min(Ai)2 ]}
max(Ai)−min(Ai) ; (2.1)
where Ai is the i-th feature. After this process, all the features will be in the region
of [−1, 1].
2.3.2 Principle Component Analysis
Another very important issue of preprocessing is dimensionality reduction. Bell-
man first proposed the term “curse of dimensionality” in 1961, which refers to the
exponential growth of hyper-volume as a function of dimensionality[95]. Most sta-
tistical learning models can be thought of as mappings from an input space to an
output space. Thus, loosely speaking, a statistical learning model needs to somehow
“monitor”, cover or represent every part of its input space in order to know how
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that part of the space should be mapped. Covering the input space takes resources,
and, in the most general case, the amount of resources needed is proportional to
the hyper-volume of the input space. The exact formulation of “resources” and
“part of the input space” depends on the type of the model and should probably be
based on the concepts of information theory and differential geometry. The curse
of dimensionality causes a model with lots of irrelevant inputs to behave relatively
badly. When the dimension of the input space is too high, the model uses almost
all its resources to represent irrelevant portions of the space. Even if a statistical
learning algorithm is able to focus on important portions of the input space, the
higher the dimensionality of the input space is, the more examples are needed to
make a reasonable sampling.
Dimensionality reduction has been the focus of preprocessing research for quite
some time. Principal Component Analysis (PCA) is the widely recognized repre-
sentative. It constructs a new set of features from the original features to minimize
the information loss when discarding any of the original features.
The basic idea in PCA is to construct new components s1, s2, . . . , sn so that they
can explain the maximum amount of variances in the input space by linear trans-
formation. PCA can be defined in an intuitive way using a recursive formulation.
Define the direction of the first principal component, say w1, by
wi = arg max‖w‖=1
E[(wT · x)2]; (2.2)
where w1 is of the same dimension as the example vector x. Thus the first principal
component is the projection on the direction in which the variance of the projection
is maximized. Having determined the first k − 1 principal components, the k-th
principal component is determined as the principal component of the residual:
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Figure 2.2: Principle component analysis of a 2D data set. The line shown is the
direction of the first principal component, which gives an optimal (in the mean-
square sense) linear reduction of dimension from 2 to 1.




In practice, the computation of the wi can be simply accomplished by using the
(example) covariance matrix E{xTx} = C. The wi are the eigenvectors of C that
correspond to the k largest eigenvalues of C.
By choosing the first n components, PCA is used to reduce the dimensionality
of the input data. One usually chooses n < N (N is the dimension of the original
feature vector). It can be proven that the representation given by PCA is an optimal
linear dimension reduction technique in the mean-square sense[39]. By this means,
noise may be reduced, as the data not contained in the n first components may be
mostly due to noise. A simple illustration of PCA is found in Figure 2.2, in which
the first principal component of a two-dimensional data set is shown.
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2.4 Machine learning theory and algorithms
2.4.1 Philosophy
A little kid can easily tell the apples from a basket of fruit. More than that, he
can exclude the rotten pieces. This problem is not very difficult since we human
beings (but not restricted to human beings) have the ability of thinking. However
automating this process turns out to be fairly complicated since at the current stage
we still have not fully understood the mechanism of the brain, and consequently we
can not build a mathematical model to simulate the thinking process of the brain
on a computer. An alternative strategy for solving this type of problem is to make
the computer learn the input/output functionality from examples, in the similar
way that children learn which are apples simply by being told which of a large
number of fruits are apples rather than by being given the precise definition of apple
from encyclopedia. The approach of using examples to train a computer model to
learn a specific concept is known as the machine learning or pattern recognition
methodology. And in particular, when the examples are input/output pairs it is
called supervised learning.
A learning problem with simple yes/no tag like outputs is defined as a binary
classification or concept learning problem. There are also multi-class classification
problems whose output will be one of a finite number of categories. A case in point is
predicting protein families from amino acid sequence. In this work, we mainly focus
on the binary classification problems since most multi-class classification problems
can be decomposed to several binary classification problems.
Mathematically, when learning the target concept, the learner is given a set of
training data X, each consisting of an instance x, along with its target concept
value f(x). Instances for whom f(x) = 1 are called positive examples, or members
2.4 Machine learning theory and algorithms 26
of the target concept. Instances for whom f(x) = −1 are called negative examples,
or nonmembers of the target concept. Thus the problem faced by the learner is to
hypothesize, or estimate the target function f . Let H denote the set of all possible
hypotheses that the learner may consider regarding the identity of the target concept.
Each hypothesis h in H represents a Boolean-valued function defined over X; that
is, h : X → {−1, 1}. The goal of the learner is to find a hypothesis h, such that
h(x) = f(x) for all x in X. In short, concept learning can be thought as the
searching through a large space of hypotheses implicitly defined by the hypothesis
representation. The goal of this search is to find the hypothesis that best fits the
training examples.
It is theoretically proved that most machine learning algorithms are capable of
representing any function[40]. But for thorny training sets they might give a hypoth-
esis that behaves like a rote learner. That is, the hypothesis correctly classifies the
data in the training set, but makes essentially uncorrelated predictions on unseen
data. Here comes, however, a more fundamental concern with machine learning al-
gorithms. That is how we can find a hypothesis consistent with not only the training
data, but also unseen data. The ability of a hypothesis to correctly classify unseen
data is known as the generalization ability. Ockham’s razor[40] is a philosophical
principle that can give us helpful hint on how to improve the generalization ability
of a machine learning model. It suggests that unnecessary complications are not
helpful, or perhaps more accurately, complications must pay for themselves by giv-
ing significant improvements in the classification rate on the training data. Thus we
expect that by minimizing the classification error on training data plus a complexity
measure of the hypothesis, the optimal hypothesis could be found.
Over the years, various classification algorithms have been developed by the ma-
chine learning community. Representatives of these algorithms are decision tree,
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artificial neural network, genetic algorithm, k-nearest neighbor learning, Bayesian
learning , support vector machine and etc. Depending on the characteristics of the
data sets being classified, certain algorithms tend to perform better than others.
In recent years, algorithms based on the support vector machine and the k–nearest
neighbors have been shown to produce reasonably good results for problems whose
features are continuous. For this reason, we are mainly interested in these two algo-
rithms. We also include the decision tree algorithm, which is the classical benchmark
for classification algorithms and can be applied universally. These algorithms are
described briefly in the following sections.
2.4.2 Decision tree
Decision tree is a learning method for approximating discrete-valued target func-
tions, in which the learned function is represented by a tree with branches. Learned
trees can also be re-represented as sets of if-then rules to improve human readability.
These learning methods are among the most popular inductive inference algorithms
and have been successfully applied to a broad range of tasks from diagnosing medical
cases to assessing credit risk of loan applicants.
Decision trees classify instances by sorting them down the tree from the root
to some leaf node. Each node in the tree specifies a test of some attribute of the
instance, and each branch descending from that node corresponds to one of the
possible values for this attribute. An instance is classified by starting at the root
node of the tree, testing the attribute specified by this node, then moving down
the tree branch according to the value of the attribute of the given example. This
process is then repeated for subtree rooted at the new node. Figure 2.3 gives an
illustration of a typical learned decision tree.
Currently many softwares have been developed for learning decision trees, like
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Figure 2.3: Illustration of the decision tree
ID3[41], CART[42] and C4.5[43]. Most of them are variations based on a core
algorithm that employs a top-down, greedy search through the space of possible
decision trees. Table 2.1 gives the basic algorithm for decision tree learning.
Table 2.2: Decision Tree Algorithm Chart
To construct a decision tree T from learning data set D:
If D contains one or more examples, all of which belongs to a single class
C, stop.
If D contains no example, the most frequent class at the parent of this node
is chosen as the class, stop.
Otherwise begin
1. Select the “most informative” attribute A
2. Partition D according to A′s value
3. Recursively construct subtrees T1, T2,. . . , for the subset of D.
The primary focus of the decision tree growing algorithm is to select which
attribute to test at which decision node in the tree. Here some technical terms from
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information theory, namely “information gain”, “gain ratio” are borrowed as the
quantitative measure of how well a given attribute separates the training examples.
In order to define information gain precisely, we need to first introduce another
measure parameter—entropy, which characterizes the impurity of an arbitrary col-
lection of examples. Given a training data set D, in the binary classification setting,
the entropy of set D is defined as:
Entropy(D) = −p⊕ log2(p⊕)− pª log2(pª); (2.5)
where p⊕ is the proportion of positive examples in D and pª is the proportion of
negative examples inD. In all calculations involving entropy we define 0 log2(0) to be
0. Thus the entropy is 1 (at its maximum value) when the collection contains equal
numbers of positive and negative examples, and the entropy is 0 if all members of D
belong to only one class, which is the stop criteria of tree splitting. More frequently,
the entropy is between 0 and 1, since the collection contains unequal numbers of
positive and negative examples.
After that, we are able to define the “information gain”, a measure of the ef-
fectiveness of an attribute in classifying the training examples. It is simply the
expected reduction in entropy caused by partitioning the examples according to
this attribute. Mathematically, the information gain Gain(D,A) of an attribute A,
relative to a collection of examples D, is defined as




where V alues(A) is the set of all possible discrete values for attribute A, and Dv
is the subset of D in which attribute A has the value v. Note the first term in the
equation (2.2) is just the entropy of the original collection D and the second term
is the expected value of the entropy after D is partitioned using attribute A. The
expected entropy described by this second term is simply the sum of the entropies
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of each subset Dv, weighted by the fraction of examples |Dv|/|D| that belongs to
Dv. Gain(D,A) is therefore the expected reduction in entropy caused by knowing
the value of attribute A.
The measure of information gain tends to favor those attributes with more pos-
sible discrete values. For example, a decision tree can be established to predict the
disease of a patient using only one attribute: the case serial number. However, such
a decision tree would probably fail when a new patient with a new case serial number
comes. Another measurement, Gain Ratio is defined to avoid this bias, which can
be calculated as follows.
GainRatio(D,A) = Gain(D,A)/SplitInformation(D,A); (2.7)
and






SplitInformation(D,A) discourages the selection of attributes with many val-
ues. Therefore, Gain Ratio is the ratio of information gained that is pertinent to
classification by branching on A.
The initial definition of decision tree is restricted to attributes that take on dis-
crete values. To incorporate continuous-valued attributes into the learned tree, we
can partition the continuous attribute values into a discrete set of intervals. For
instance, for an attribute like temperature that has continuous values, the ID3 al-
gorithm can dynamically create a new Boolean attribute A′ whose value is low if
the temperature is below 20oC and high otherwise. The only question is how to
select the best value for the threshold. Intuitively, we would like to pick a threshold
that produces the greatest information gain. By sorting the examples according
to the continuous attribute A, then identifying adjacent examples that differ in
their class labels, we can generate a set of candidate thresholds midway between the
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corresponding values of A. It can be proven that the value of the threshold that max-
imizes information gain always lie at such a boundary. These candidate thresholds
can then be evaluated by computing the information gain associated. This dynam-
ically created Boolean attribute can then compete with the other discrete–valued
candidate attributes available for growing the decision tree.
In principle, the above decision tree algorithm can be used to grow a tree with
as many branches as to perfectly classify all the training examples. While this is
sometimes a reasonable strategy, in most cases it leads to difficulties when there is
noise in the data, or when the size of the training data set is too small to give a
representative sample of the real-world problem. In either of these cases, this simple
algorithm will produce trees that over-fit the training examples. Therefore, after
the tree is constructed, a pruning process is applied to gradually remove decision
nodes that give the least improvements on accuracy and assign to these nodes the
class label of the majority of remaining examples. In this case, the prune level will
be a free parameter to be optimized in the decision tree induction, which controls
the complexity of the tree.
2.4.3 K-Nearest Neighbor
K-Nearest Neighbor (knn) is a well known and widely used instance-based classifica-
tion algorithm due to its conceptual simplicity, general applicability and efficiency.
Learning in knn consists of simply storing the presented training data. When a new
query instance is encountered, a set of similar related instances is retrieved from
memory and used to classify the new query.
The basic idea behind this classification paradigm is first to compute the simi-
larity between a query instance and all the examples in the training data set, then
select the k most similar training examples, and finally to determine the class label
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of the query instance based on the class labels of its k nearest neighbors.
Two steps are critical to the performance of the k-Nearest Neighbor. The first
is how to measure the similarity between a query instance and a training example.
For data sets in which the examples are represented by multi-dimensional vectors,
like our application, the measurement commonly used to compute the similarity
is the Euclidean distance. More precisely, suppose an arbitrary instance x can be
described by the feature vector {a1(x), a2(x), . . . , an(x)}, where ar(x) denotes the
value of the rth attribute of instance x, r = 1, 2, . . . , n. Then the distance between





The second problem is how to determine the class label of the query instance
based on the class labels of its nearest neighbors. The most straightforward strategy
is that the minority should be subordinate to the majority. In other words, the query
instance will be classified to the class to which most of the k-nearest neighbors






where f(xi) is the class label of the ith nearest neighbor xi, either +1 or −1.
In the k-Nearest Neighbor learning, the value of k is required. It has been found
that k <
√
N is a general criterion that should be met for good results, where
N is the total number of training examples. Therefore, the number of effective
nearest neighbors k will be a free parameter in the k-nearest neighbor algorithm to
be optimized according to test results.
However, this knn algorithm is incompetent for the problems showed in Figure
2.4. On the left, the 1-nearest neighbor algorithm classifies xq positive, whereas
5-nearest neighbor classifies it as negative. On the right, the 4-nearest neighbor
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Figure 2.4: Illustration of k-nearest neighbor
algorithm will not be able to assign the query instance a label based on its 4-nearest
neighbors which are two positive and two negative.
One feasible refinement is to weight the contribution of each of the k neighbors
according to their distance to the query point xq, giving greater weight to closer











The distance-weighted k -Nearest Neighbor algorithm is a highly effective induc-
tive inference method for many practical problems. It is robust to noisy training
data and quite effective when it is provided a sufficiently large set of training data.
Note that by taking the weighted average of the k neighbors nearest to the query
point, it can smooth out the impact of isolated noisy training examples.
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2.4.4 Support vector machine
Support vector machine was first introduced in 1995 by Vapnik and his co-workers[44].
Then the research on both SVM theory and application has exploded in the last
decade. Now it has become one of the most powerful statistical learning methods and
has outperformed many other machine learning methods in a wide variety of applica-
tions, such as text categorization[45, 46], hand-written digit recognition[47], image
classification and object detection[48, 49], flood stage forecasting[50], micro-array
gene data analysis[51], protein folding recognition[52], protein secondary structure
prediction[53], protein-protein interaction prediction[54] and etc.
The main idea of support vector machine is to construct a hyperplane in a
high-dimensional space as the decision surface in such a way that the margin of
separation between positive and negative examples is maximized. In order to find
such an optimal hyperplane, special “kernels” are introduced to help automatically
conduct nonlinear mapping from the input space onto a feature space in which the
training examples can be linearly separated.
Let us consider a training data set consisting of n examples. Each example is
denoted as (xi, yi), i = 1, 2, . . . , n. where yi ∈ {−1,+1} is the corresponding target
output. Given a weight vector w and a bias b (See Figure 2.5), it is assumed that
these examples can be separated by a hyperplane with a margin of γ:
wT · xi + b ≥ +1, for yi = +1; (2.13)
wT · xi + b ≤ −1, for yi = −1; (2.14)
Equation (2.13) and (2.14) can be combined into a single inequality:
yi(w
T · xi + b) ≥ 1, for i = 1, 2, . . . , n; (2.15)
The objective of SVM is to determine the optimal weight wo and optimal bias bo
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Figure 2.5: Definition of hyperplane and margin (The square dots and circular dots
represents samples of class +1 and class -1, respectively)
so that the corresponding hyperplane, namely the Optimal Separating Hyperplane
(OSH), separates the positive and negative training data with maximum margin,
which is expected to produce the best generalization performance (See Figure 2.6).
The width of the two corresponding margins is
γ(w, b) = min
{x|y=+1}
wT · x
‖ w ‖ − max{x|y=−1}
wT · x
‖ w ‖ (2.16)
Given the constraint of equation (2.15), one obtains
γmax = γ(wo, bo) =
2
‖ wo ‖ (2.17)




wTw, for i = 1, 2, . . . , n; (2.18)
subject to yi(w
T · xi + b) ≥ 1.
We may solve the constrained optimization problem using the method of La-
grange multiplier:
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Figure 2.6: Available separating hyperplanes and Optimal Separating Hyperplane
First, we construct the primal Lagrangian function:







T · xi + b)− 1]; (2.19)
where the auxiliary nonnegative optimization problem is determined by the saddle
point of the function L(w, b, α), which has to be minimized with respect to w and
b. By setting ∂L
∂w







αiyi = 0; (2.21)











αiαjyiyj(xi · xj) (2.22)
subject to the constraints
∑n
i=1 αiyi = 0 and αi ≥ 0 for i = 1, 2, . . . , n.
There are standard algorithms like sequential minimization optimization[55] and
decomposition algorithm[56] to solve this optimization problem.
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The examples that have positive coefficients αi satisfy the condition of yi(w ·xi+
b) = 1, and thus are located on the margin hyperplanes. They form the boundary
of the margin and are called Support Vectors (SVs).






T · xi) + max{xi|y=−1}(wo
T · xi)]; (2.23)
After determination of Support Vectors and bias, the decision function that









T · x) + bo]; (2.24)
The linear classifier based on the above scheme can be easy to handle, but they
pose severe restrictions on the learning task. The target concept may be too complex
to be expressed as a linear combination of the given attributes. This problem can
be overcome by an approach called kernel technique1. Its general idea is to map the
training data set X from the input space into a high-dimensional feature space F
via a Mercer kernel2 operator K and separate it there by a linear classifier. This
will result in a nonlinear classifier in input space.
Mathematically, let Φ denote an implicit mapping function from the input space
to the feature space F. Then all the above equations are transformed into the fol-
lowing form when we substitute xi and the inner product in input space (xi · x) by
Φ(xi) and inner-product kernel K(xi,x) respectively.
Here the Kernel function can be expressed as a legitimate inner product in a
feature space:
K(xi,x) = [Φ(xi) · Φ(x)]; (2.25)
1Soft margin is another possible approach which will be found in many references.
2Mercer’s theorem states that any positive definite kernel K(x, y) can be expressed as a dot
product in a high-dimensional space.
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Figure 2.7: Projecting the training data nonlinearly into a higher-dimensional fea-
ture space and constructing a hyperplane to separate positive and negative data
with maximum margin there.











subjects to the constraints:
∑n
i=1 αiyi = 0 and αi ≥ 0, for i = 1, 2, . . . , n.


















In Table 2.3 we summarize the most prevalent kernel functions.
2.5 Performance analysis and evaluation
In addition to preprocessing, another important issue of machine learning is the
performance analysis and evaluation. We might describe the step as an evaluation
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K(xi,x), i = 1, 2, . . . , n
Polynomial Kernel (xTxi + 1)
p







) The width σ2, common to
all the kernels, is specified
a priori by the user
Two-layer perceptron tanh(β0x
Txi + β1)
Mercer’s theorem is satisfied
only for some values of β0
and β1
of the performance of a proposed solution to the concept learning task. Most com-
monly used error measurement indicators and error estimating strategies (mainly
independent testing data set) are introduced in this section.
2.5.1 Training versus Testing
In Figure 2.8 (the left two rectangles), we see two views of collected data. The first
one has one data set that contains all available data. The second view has two
samples, the larger one for training and the smaller one for evaluation.
In most applications, we prefer the second strategy. This is because even though
it is very easy to get exceptional results when we solely rely on training data, these
results are likely not generalize to new examples. Researchers have developed many
training techniques that reduce the likelihood of “overfitting” to the training data.
An effective way is to hide some data and then do a fair comparison of training
results to unseen test results. Of course, one could wait until new data arrives
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Figure 2.8: Data organization for empirical evaluation
during application of the solution, but it is wise to test performance prior to actual
application. It prevents unexpected poor results and gives the developers time to
extract the best performance from the application system.
Usually in machine learning algorithms, free parameters need to be tuned to
obtain a good classification model, such as the k in knn and the Gaussian kernel
width σ used in SVM. In this work, in order to find the optimal parameters for each
algorithm, I apply 10-fold cross validation to training sets. Then a model is trained
using all the training data with the parameters selected. This procedure ensures
that the testing data are never seen during the model training stage.
K-fold cross validation is a model evaluation method that is widely believed to
be better than residuals. The data set is divided into k subsets, and the holdout
method is repeated k times. Each time, one of the k subsets is used as the testing
set and the other k − 1 subsets are put together to form a training set. Then the
average error across all k trials is computed. The advantage of this method is that
it matters less how the data gets divided. Every data point gets to be in a testing
set exactly once, and gets to be in a training set k − 1 times. The disadvantage
of this method is that the training algorithm has to be rerun from scratch k times,
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which means it takes k times as much computation to make an evaluation. The
variance of the resulting estimate is reduced as k is increased. Ron Kohavi suggests
that for many real-world datasets, the best method to use is 10-fold stratified cross
validation, even if the computation power allow using more folds[58].
2.5.2 Measuring error
For classification problem, we say the measurement of performance is the measure
of error. If we confine our goal to measuring an overall rate of error, we can readily
reverse the computation and speak in terms of accuracy. However, many times our
interest is not just in overall performance. Instead, as we know that a predictor yields
different types of errors, our attention will frequently focus on the specific breakdown
of error, where not all errors are treated equally important. Different types of errors
and how they influence our interpretation of performance are discussed as follows.
2.5.2.1 Confusion metrics
When talking about performance evaluation, people firstly think of Confusion Ma-
trix, which is the most simple and informative way to analyze the behavior of a
classifier. It contains information about actual and predicted classifications done by
a classification system. Performance of such systems is commonly evaluated using
the data in the matrix. The following table shows the confusion matrix for a 2-class
classifier. TP is the number of correctly classified positive examples. TN is the
number of correctly classified negative examples. FP is the number of negative ex-
amples which are predicted positive. FN is the number of positive examples which
are predicted negative.
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Table 2.4: A confusion matrix for binary classification
Actual Labels
Positive Negative
Predicted Positive TP FP
Labels Negative FN TN
2.5.2.2 Precision, Recall, and the F Measure
Although confusion matrix gives a very informative method to evaluate the classifi-
cation performance, it is not a convenient measurement that can be used to compare
two or more models and tell which one is better than the others. For this purpose,
single-value measurement need to be defined.
Accuracy =
TP + TN
TP + FN + TN + FP
; (2.29)
For drug discovery applications, there is usually a large number of negative
data. A classifier can achieve a very high accuracy by simply saying that all data
are negative. It is thus useful to measure the classification performance by ignoring
correctly predicted negative data. Three ratios have achieved particular prominence:














An alternative way of evaluating a model’s performance is sensitivity 3 and speci-
ficity. I also include them as a set of measurement in this work since they are widely










This chapter presents some issues regarding the practical implementation that ma-
chine learning approaches face. They are very important to the success of a machine
learning model. Key points to remember include:
• Data preparation is the art of wringing the most valuable information out of
the available data whereas data mining is the art of discovering meaningful
patterns in data.
• Molecular descriptors are borrowed from SAR and QSAR to encode compound
structure information numerically.
• Preprocessing techniques, such as normalization and PCA, can influence the
performance of many data mining algorithms.
• Machine learning addresses the question of how to build computer models that
improve their performance through experience for tasks in different fields. Al-
gorithms like decision tree, k-nearest neighbor and support vector machine
draw on ideas from a diverse set of discipline, including artificial intelligence,
probability and statistics, computational complexity, information theory, con-
trol theory and philosophy.
3Sensitivity is exactly the same as Recall, defined by Equation 2.31.
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• To evaluate the performance of different machine learning algorithms, two data
sets are needed: training set and testing set. And 10-fold cross-validation is
recommended in training stage.
In order to evaluate different classification and preprocessing techniques, an ef-
ficient tool to implement different algorithms is needed. Here in this work, I choose
MatLab as the programming environment since the matrix operation provided by
MatLab makes the representation of numerical data and implementation of the dif-
ferent algorithms much easier. Most programs including normalization, k-nearest
neighbor and SVM are implemented with MatLab R13 licensed from NUS. Whilst
decision tree program I use is C4.5 by Quinlan[43], which is downloadable from
http://www.cse.unsw.edu.au/∼quinlan/.
The support vector machine algorithm was implemented with a Gaussian ker-
nel. This is because the Gaussian kernel always performs better than others in our
previous studies of protein function classification[59, 60].
All the experiments were carried on a Dell Optiplex GX240 computer with one
2.4GHz Intel Pentium IV CPU and 512M memory.
Chapter 3
Antagonist prediction of the therapeutic
target–5-HT2 receptor
In this chapter, the three machine learning methods described in Chapter 2, namely
decision tree, kNN and SVM are applied to the antagonist prediction of the thera-
peutic target, 5-hydroxytryptamine 2 (5-HT2) receptor. The most potent approach
is identified based on the the experimental results of the 5-HT2 receptor antagonist
data.
In section 3.1 the biology and pharmacology of 5-HT2 receptor and 5-HT2 re-
ceptor antagonism are introduced. It is followed by the detailed description of data
preparation procedure and experimental design. The results obtained are then pre-
sented and discussed in section 3.3. In section 3.4, a summary is given.
3.1 Introduction
3.1.1 5-HT and 5-HT receptor subtypes
Serotonin (5-hydroxytryptamine, 5-HT) is a major neurotransmitter in the brain.
It mediates a wide range of physiological functions, such as anxiety, depression,
45
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Figure 3.1: The chemical structure of serotonin
schizophrenia, drug abuse, sleep, dreaming, hallucinogenic activity, headache, car-
diovascular disorders and appetite control, by interacting with multiple receptors.
Seven distinct families of 5-HT receptors have been identified (5-HT1—5-HT7), and
subpopulation have been described for several of these families[64] (See Table 3.1).
The profusion of 5-HT receptors should eventually allow a better understanding
of the different and complex processes in which 5-HT is involved. In this thesis, I
am primarily interested in 5-HT2 receptors. A brief introduction of 5-HT2 receptors,
their antagonists1 and clinical implication is given below.
3.1.2 5-HT2 receptors and their antagonism
Serotonin receptors were firstly divided into 5-HT1 and 5-HT2 receptor families
in 1979[62] and the latter were subsequently divided into subfamilies 5-HT2A, 5-
HT2B, and 5-HT2C (formerly 5-HT1C) receptors. There is approximately 70-80%
sequence homology among the three receptor subtypes[63]. Many of the original
agents thought to be 5-HT2 selective, including standard antagonists such as ke-
tanserin and the agonists DOB and DOI, were later shown to bind nonselectively to
1Agonist is a chemical that binds to a receptor and activates it, producing a pharmacological
response (e.g. contraction, relaxation, secretion, enzyme activation, etc.). Antagonist is a chem-
ical that binds to a receptor and blocks it, producing no response but preventing agonists from
binding, or attaching, to the receptor. It is similar to inhibitor functionally. Inhibitor is a chemical
compound that has the effect of blocking or slowing an enzyme.
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Table 3.1: Overview of 5-HT receptor subtypes
G protein-coupled receptors
5-HT1 “Family”: 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT1F
5-HTdro2A, 5-HTdro2B, 5-HTsnail
5-HT7 “Family”: 5-HT7, 5-HTdrol
5-HT5 “Family”: 5-HT5A, 5-HT5B
5-HT2 “Family”: 5-HT2A, 5-HT2B, 5-HT2C
5-HT6 “Family”: 5-HT6





both 5-HT2A and 5-HT2C receptors.
It is still not known with confidence specifically what pharmacological effects are
related to what 5-HT2 subpopulation. But results with the newer agents indicate
that 5-HT2A receptors might be involved in psychosis, depression, and hallucino-
genic activity[64, 65, 70], and that 5-HT2C receptors may play a role in obsessive-
compulsive disorders, panic, anxiety, and depression[66]. In the periphery, 5-HT2B
receptors seem to be involved in muscle contraction[67, 68]; however their function
in the CNS is still a matter of speculation. Based on some preliminary studies, and
on their central distribution in brain, it was suggested that 5-HT2B receptors might
be involved in anxiety, cognition, food intake, neuroendocrine regulation, locomotor
coordination, and balance[69]. Several novel approaches may assist further eluci-
dating the roles of these subpopulations and the developing of site selective agents.
For example, site directed mutagenesis and synthesis of chimeric receptors[70, 71],
coupled with the use of molecular graphics modeling studies[70, 72], are beginning
to identify what portions of the receptors are important for ligand binding.
In this work, I do not distinguish between the subpopulations of the 5-HT2
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family and do antagonist prediction for the whole 5-HT2 receptor family since 5-
HT2A, 5-HT2B and 5-HT2C receptors are so closely related, making it rather difficult
to design agents selective for any one of the subpopulations[73]. This is also due to
the fact that the nomenclature scattered in different references is quite confusing and
not unified. In addition, from the perspective of machine learning algorithms, the
number of selective antagonists for a particular subpopulation may not be enough
to train an accurate model; while combining three subpopulations together may be
better.
Various compounds, which have antagonistic properties on 5-HT2 receptor, are
currently available in markets. For instance, clozapine is a prevalent drug in treat-
ment of schizophrenia. Besides, a lot of other 5HT2 antagonists are currently under
development and some of them have already entered the clinical trial stage, such
as zipraisdone (by Pfizer), Eplivanserin (by Sanofi-Synthe´labo) and Org-5222 (by
Organon Laboratories). New 5HT2 antagonists are expected to help in develop-
ing drugs of high efficacy, low toxicity and personalized treatments for physiologic
disorders.
3.2 Data preparation
In order to train a model that can predict whether a molecular structure represents
a potential 5-HT2 receptor antagonist or not, examples of both classes, compounds
known to be 5-HT2 receptor antagonists (positive examples) and compounds not
known to be 5-HT2 receptor antagonists (negative examples) are needed. While the
former is readily available in many references, it is much harder to come up with neg-
ative examples. My approach is to take the well-established inhibitors/antagonists
of other proteins which are dissimilar to 5-HT2 receptor in both structure and func-
tion as representatives of negative examples. Although some of them might also
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have potential inhibitory effect on 5-HT2 receptor, it is reasonable to assume that
the chances are very slim for these well-studied inhibitors of other irrelevant pro-
teins to be 5-HT2 receptor antagonists. Therefore it is safe to say that such a data
collection method is able to represent the real situation.
In this work, 106 different 5-HT2 receptor antagonists were collected from var-
ious references in PubMed. 1366 negative examples were collected from the in-
hibitors/antagonists of a group of “negative proteins”, which are proteins that are
not functionally and structurally related to 5-HT2 receptor. The approach I used to
obtain the group of “negative proteins” is the same as the approaches described by
Cai et al[75] described for generating negative protein data sets for protein function
classification.
Specifically, a total of 1097 proteins from TTD database[23] are selected as “neg-
ative proteins”, expect for dopaminergic, histaminergic and adrenergic neurotrans-
mitter receptors and other serotonin receptors. This is because these proteins are
very similar to 5-HT2 receptor. The ligands binding to these receptors and those
binding to 5-HT2 overlap to a certain extent. For example, spiperone (See Figure
3.2) which has been employed as a 5-HT2 antagonist, is also a dopamine antagonist,
a 5-HT1A antagonist and a 5-HT7 antagonist[74]. These proteins (like the dopamine
receptor, 5-HT1A and 5-HT7 in this example) must be excluded from the “negative
proteins”, otherwise it will lead to confusion or conflict during the machine learning
model training time.
The 2D structures of the 5-HT2 antagonists and “non-” 5-HT2 antagonists are
found in ChemIDPlus database online. To calculate the 159 descriptors for each
structure, the 2D structures are converted into 3D structures using Concord 4.0.12
2CONCORDTM is a product of Tripos. It sets the industry standard for extremely rapid con-
version of 2D (or even crude 3D) input to accurate, geometry-optimized 3D structures. Currently
it is most often used for the conversion of large corporate and commercial databases worldwide.
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Figure 3.2: The chemical structure of spiperone, an antagonist for multiple receptors.
licensed from NUS.
The structures of the compounds of the two classes were cleaned in a way similar
to the one described by Sadowski J. et al[76].
• Unsuitable compounds were removed (e.g. acid halides, anhydrides, metal
containing compounds, compounds with a molecular weight below 150 or above
1000, etc.);
• Counterions and solvent molecules were removed;
• Duplicates within each class were removed;
• Compounds shared by both class were removed from negative examples.
Final data include 106 antagonists and 1272 “non-” antagonists of 5-HT2 recep-
tor.
These compounds are further separated into two sets: training and testing sets.
The training set is used by different machine learning methods to develop a statistical
model and the testing set is used to evaluate the classification performance of the
model. The split method used here was described by R. W. Kennard and L. A.
Stone[77]. The ratio is set to roughly 8 : 2. For algorithms like SVM and k-NN,
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free parameters need to be tuned. Therefore 10-fold cross validation is performed
during training to help find the optimal free parameters. For decision tree, since the
software I used is C4.5 package developed by Quinlan et al[43], the parameter tuning
is implemented inside. Hence I used all the data in the training set without cross-
validation to train a model. This is to ensure fair comparison of the performance
which is based on independent testing set.







Training set 85 1018 1103
Testing set 21 254 275
Total No. 106 1272 1378
Now that the data have been collected and split into training and testing set,
these data are further processed by scaling and PCA techniques as discussed in
Chapter 2. Figure 3.3 shows the PCA result of the training data. From it, we can
see that without loss of any variances encoded in the data set, we can reduce 46
redundant dimensions out of 159 dimensions. Keeping 99% of the variances, 101
dimensions can be removed. Keeping 90% of the variances, 136 dimensions can
be removed. It is generally believed that the low variances dimensions are highly
possible to be dimensions of noises. Therefore the PCA dimensionality reduction
are expected to shorten the calculation time and improve the signal-to-noise ratio in
data. Taking the noise of data into consideration, I choose to construct new training
data sets with the first n principal components representing 90%, 99% and 100% of
variances which correspond to n = 23, n = 58, and n = 113 respectively.
To assess the prediction capability of different algorithms, the testing data shall
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Figure 3.3: The number of principal components VS the percentage of total variance
they represent.
undergo exactly the same transformation as training data.
3.3 Prediction results and analysis
The preprocessed data are then subjected to different machine learning analysis.
The results are discussed in the following subsections.
3.3.1 Decision tree prediction
The unpruned decision tree C4.5 generated for original data is shown in Figure 3.4.
The feature x86, x134, . . ., correspond to the 86th descriptor, 134th descriptor,. . .,
in Table 2.1. A branch node is like {x134 <= −0.43652 :}. It means the data
falling into this category are still messy and need to be further branched. A decision
leaf is like {x93 > −0.057129 : 1 (2)}. This particular example means that
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there are two examples falling into this leaf {x93 > −0.057129} under all other
parent branches and they are predicted to be positive, or 5-HT2 receptor antagonists.
And two compounds are true positive while no compound is negative but predicted
positive. In some cases, the number in brackets may be followed by a second number
(e.g., {x106 > −0.52536 : −1 (3/1)}). Here, the second value (1) equals the
number of classification errors encountered out of the total number of classifications
made from the training data in that particular path of the decision tree (3)3.
Table 3.3: Summary of the decision tree’s performance on original and PCA pre-
processed data sets
Measurement On original data
On the data sets after PCA
113-dimension 58-dimension 23-dimension
Precision 88.23% 100.00% 76.92% 100.00%
Recall/Sensitivity 71.43% 71.43% 47.62% 57.14%
F measure 78.95% 83.33% 58.82% 72.72%
Specificity 99.21% 100.00% 98.82% 100.00%
Table 3.3 gives the performance evaluation on the four testing data sets. The
precision, recall, F measure, sensitivity and specificity are compared on the four
data sets. It is found that in general the prediction accuracy for negative examples
are quite high. This is expected as in training set, the number of negative examples
are more than 10 times greater than that of positive examples, which may give more
information on the characteristics of negative examples. As for positive examples,
3The threshold values used in this decision tree are those after scaling. To test unseen instances,
they have to be scaled to [−1, 1] using the strategy described in Section 2.3.1. On original data,
no PCA preprocessing is done. The next few chapters will also follow this convention.
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Figure 3.4: The decision tree generated for 5-HT2 receptor antagonists
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the original data set and 113 principal components(PCs) data set give the highest
recall (sensitivity) value of 71.43%, which means 15 positive examples out of 21
are predicted correctly. On a whole, the algorithm performs best on the 113 PCs
data set, whose Fmeasure is as high as 83.33%, then are original data set, 23 PCs
data set, and 58 PCs data set, in the order of performance decrease. Last but not
least, it is interesting to see that when discarding 1% variances, the 58 PCs data
set gives lower accuracy compared to the 23 PCs data set discarding 10% variances.
It indicates that the noise of the data are not concentrated in the smallest variance
region, but in the dimensions where the variances are bigger.
3.3.2 K-Nearest Neighbor prediction
The parameter k used in knn is scanned in the range of 1, 2, . . . , 33. The number
“33” is calculated as the square root of the number of training examples. Such a large
scanning range normally ensures that the optimal performance can be found. In the
application of drug design, k is tuned in the direction of improving Fmeasure. This
is because that in the training data, the number of negative examples are 10 times
greater that of positive examples, and the prediction accuracy for negative examples
are all above 98%. So discovering positive examples or improving prediction accuracy
on positive examples becomes the priority. Fmeasure is an ideal measurement
because it balances between how many positive examples are recognized and how
many examples are true positive among those predicted positive ones.
In order to find the optimal k, the Fmeasure is plotted against k. Figure 3.5
illustrates the parameter tuning process. The best Fmeasures on the original data
set, 113 PCs data set, 58 PCs data set and 23 PCs data set are 66.15%, 66.15%,
67.18% and 68.00% respectively. And the maximum Fmeasure are reached when k
is set to 7, 7, 7 and 5 respectively. Finally the classification results are measured on
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Figure 3.5: The k-NN parameter tuning process based on 10-fold cross validation
testing data sets using the models trained with these optimal k values (See Table
3.4).
Table 3.4: Summary of the knn’s performance on original and PCA preprocessed
testing sets
Measurement On original data
On the data sets after PCA
113-dimension 58-dimension 23-dimension
Precision 100.00% 100.00% 100.00% 100.00%
Recall/Sensitivity 71.43% 71.43% 66.67% 66.67%
F measure 83.33% 83.33% 80.00% 80.00%
Specificity 99.29% 99.29% 98.57% 98.57%
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Figure 3.6: The SVM parameter tuning process based on 10-fold cross validation
Generally speaking, as a very simple approach, the knn gives a really good
performance, compared to decision tree. However, this superiority is only obvious for
58 principal components consisting data set and 23 principal components consisting
data set. Decision tree and knn give exactly the same and best results on 113
principal components consisting data set. The best Fmeasure is 83.33% and the
best recall value is 71.43%.
3.3.3 SVM prediction
SVMs are trained with the free parameter of Gaussian kernel width (σ), scanned
in the range of [0, . . . , 11] with an interval of 0.2, which is the empirical range that
gives optimal classification results on chemical compounds classification.
For every σ, the training data set is divided into 10 subsets, and the holdout
method is repeated 10 times. Each time, one of the 10 subsets is used as the small
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testing set and the other 9 subsets are put together to form a small training set. Then
the average Fmeasure across all 10 trials is computed. In the end, Fmeasure are
plotted against σ, on four training sets (See Figure 3.6). By optimizing Fmeasure,
the best σ found are 2.0, 2.0, 2.2 and 1.0. Finally the classification performance
are measured on four testing sets with their optimal σ values. The summary of the
results is shown in Table 3.5. The Fmeasure calculated on the four testing data
sets are 92.31%, 92.31%, 87.47%, and 77.78% for the original data set and the data
sets consisting of first 113, 58, and 23 principal components respectively.
Table 3.5: Summary of the SVM’s performance on original and PCA preprocessed
testing sets
Measurement On original data
On the data sets after PCA
113-dimension 58-dimension 23-dimension
Precision 100.00% 100.00% 100.00% 93.33%
Recall/Sensitivity 85.71% 85.71% 80.95% 66.67%
F measure 92.31% 92.31% 87.47% 77.78%
Specificity 100.00% 100.00% 100.00% 99.61%
Such results are much better than those of decision tree and knn. The best recall
(sensitivity) we get by SVM is more than 14% higher than that of decision tree and
knn. And the Fmeasure, precision and specificity are also higher than those of
decision tree and knn to different extent. This indicates the 5-HT2 inhibitor data
in the input space are, from a machine learning perspective, quite complex and
require more powerful classification algorithm. Consistent with the previous two
classification algorithms, the best result with SVM is also obtained from the data
set that consists of the 113 principal components representing all the variances.
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Therefore, PCA preprocessing does help to significantly reduce the computation
load required for large data set, as a result of reduced number of features, from 159
to 113 in this case.
3.4 Summary
The neurotransmitter serotonin mediates a wide range of physiological functions
including a number of normal human functions (e.g. sleep, sexual activity and
appetite) as well as human disorders (e.g. migraine, depression and anxiety), by
interacting with multiple receptors. Among these receptors, 5-HT2 receptors have
been reported to play important roles in these pathological and psychopathologi-
cal conditions. New 5HT2 antagonists are expected to help develop personalized
treatments of high efficacy and low toxicity for physiologic disorders.
In this chapter, 106 5-HT2 antagonists are collected manually from different
references. Moreover, 1272 chemicals which bind to a wide range of proteins, ex-
cluding 5-HT2 homological proteins, were selected as a diversified sample of “non-”
5-HT2 antagonists. These data are further split into training and testing data sets
according to the method of Kennard and Stone[77].
Different machine learning classifiers, namely decision tree, knn and SVM are
built using training data sets. The classification results are measured and compared
on original testing data and testing data sets consisting of the first 113, 58, and 23
principal components. The results show:
• The overall performance is decent. The most important measurement Fmeasure
from decision tree, knn and SVM reach are 83.33%, 83.33% and 92.31% re-
spectively on the optimal data set—the data set consisting of 113 principal
components. SVM beats decision tree and knn by nearly 9%.
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• PCA seems useful in dimensionality reduction. The data set that gives the
best results by all the three approaches is made up of the first 113 principal
components, which corresponds to the minimum dimensions that keep 100%
of the original variances.
• The fact that the PCA processed data set keeping 100% variances give better
results than those keeping 99% and 90% variances demonstrates the descriptors
I used in this work are capable of characterizing these chemicals for this task.
But it might be necessary to reorganize the 159 descriptors and remove those
redundant ones since 113 principal components are able to represent all the
100% variances in the training data set.
In later chapters, these methods will be tested for the inhibitor prediction for an
enzyme target–cholinesterase and an ADME associated protein–CYP3A4.
Chapter 4
Inhibitor prediction of the therapeutic
target–Cholinesterase
Enzymes are known to cover 44% of the total drug targets available[23]. Therefore
they can not be missed out for the test of new lead identification techniques. In this
chapter, cholinesterase is selected as the representative of enzyme targets. A set
of compounds that have inhibitory effects on cholinesterase are collected. Decision
tree, knn and SVM are evaluated for their predictive capacity of identifying this
class of compounds.
Specifically, in section 4.1, the chemistry and biology of cholinesterase and ther-
apeutic application of cholinesterase inhibition are introduced. Then the detailed
description of data preparation procedure and experimental design is given in sec-
tion 4.2. The results obtained are then presented and discussed in section 4.3. In
section 4.4, a short summary is given.
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Figure 4.1: The chemistry of acetylcholine
4.1 Introduction
4.1.1 Cholinergic transmission
Acetylcholine is the chemical mediator of nerve impulses at all (sympathetic and
parasympathetic) autonomic ganglia, the post ganglionic parasympathetic neuroef-
fector junction, the neuromuscular junction, and some parts of the central nervous
system.
Acetylcholine’s synthesis is controlled by the enzyme choline acetyltransterase,
which mediates the transfer of an acetyl group from acetyl coenzyme A to choline,
a normal constituent of the diet. This synthetic reaction (1) is depicted as going
from left to right in Figure 4.1.
Following its release from vesicles at the nerve endings, acetylcholine interacts
with the cholinergic receptor to initiate a response. Acetylcholine is then very rapidly
hydrolyzed and inactivated by the enzyme acetylcholinesterase. This inactivation
reaction (2) is depicted as going from right to left in Figure 4.1. Choline, one of
the products of this reaction, is taken up by the nerve endings responsible for its
release, and is reused for the synthesis of new molecules of acetylcholine.
4.1.2 Biological function of Cholinesterase
Cholinesterase (ChE) are a family of related enzymes that hydrolyze choline esters
at a very fast rate. The major biological function of ChE is to terminate the impulse
4.1 Introduction 63
transmission by acetylcholine at cholinergic nerve endings in synapses or in effector
organs.
These enzymes have been further classified on the basis of substrate specificity
and sensitivity to various inhibitors. Those enzymes which preferentially hydrolyse
acetyl esters such as acetylcholine (ACh) are called acetylcholinesterase (AChE) or
acetylcholine acetylhydrolase (EC 3.1.1.7), and those which prefer other types of es-
ters such as butyrylcholine are termed butyrylcholinesterase (BChE) or acylcholine
acylhydrolase (EC 3.1.1.8). BChE is also known as pseudocholinesterase, non- spe-
cific cholinesterase, or simply cholinesterase. The last term has led to confusion,
and in this thesis the term cholinesterase will refer to all choline ester hydrolysing
enzymes, irrespective of their substrate specificity.
The main function of AChE is the rapid hydrolysis of the neurotransmitter ACh
at cholinergic synapses. The hydrolysis reaction proceeds by nucleophilic attack of
the carbonyl carbon, acylating the enzyme and liberating choline. This is followed
by a rapid hydrolysis of the acylated enzyme yielding acetic acid, and the restoration
of the esteratic site[78].
The function of BChE remains a puzzle. It has no known specific natural sub-
strate, although it is capable of hydrolysing ACh. It has been suggested that BChE
acts as a scavenging enzyme in the detoxification of natural compounds[79]. Cer-
tain human individuals have a mutant BChE which lacks the ability to hydrolyse
succinyl choline. In rare individuals the complete BChE gene is missing. Neither of
these cases result in any apparent physiological consequence. There is however an
important clinical implication; succinyl choline is commonly used during tracheal in-
tubation in the administration of inhalation anaesthetics, and causes post operative
apnoea in these people[80].
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4.1.3 Cholinesterase inhibitions
Cholinesterase inhibitors (also called anticholinesterase agents) inhibit cholinesterase
and thus slow down the hydrolysis of acetylcholine. This inhibition permits the
buildup of acetylcholine at the receptor site and causes more intensive and prolonged
cholinergic activation. The resulting pharmacological effects are qualitatively similar
to those observed after simulation of cholinergic nerves, although quantitatively of
far greater magnitude. Cholinesterase inhibition have both desirable therapeutic
effects and undesirable therapeutic effects, which are discussed separately below.
Some cholinesterase inhibitors have been used as medicine for a long time. For
example, Physostigmine is used to treat certain types of glaucoma1 for more than
a century. Neostigmine was developed in the early 1930s for management of myas-
thenia gravis; Ambenonium was developed later for this same purpose, as well as
Pyridostigmine bromide[81]. All these compounds belong to the chemical class of
carbamate.
More recently, cholinesterase inhibitors are developed to treat Alzheimer’s disease
(AD). Alzheimer’s disease is a neurodegenerative condition characterized by progres-
sive deficits in memory and cognition, together with impairment in the ability to
perform activities of daily living[82, 83]. It is prevalent in aged people worldwide and
has stimulated many scientists to focus on the research aiming at identifying patho-
genesis of this disease and at discovering effective pharmaceuticals for it. However,
despite these efforts, a cure for this disease remains to be found. Currently only one
class of medications has been extensively evaluated and showed efficiency for AD
symptoms. These are cholinesterase inhibitors. Tacrine, donepezil, rivastigmine and
galantamine are the representatives that have been approved by the US Food and
1It is a disease characterized by increased intraocular pressure, which if untreated, will ulti-
mately result in damage to the optic nerve.
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Drug Administration (FDA) and other governmental agencies for the treatment of
AD.
On the other hand, cholinesterase inhibitors are also widely used as agricul-
tural and household insecticides, and even chemical warfare agents (e.g. nerve
gases such as sarin and soman). These compounds belong to the chemical class
of organophosphate. Their acute toxicity is mainly due to the buildup of ACh at
cholinergic synapses. Signs and symptoms of overexposure to these cholinesterase
inhibitor include tiredness, dizziness, nausea and blurred vision; headache, sweat-
ing, tearing, drooling, vomiting, tunnel vision, and twitching; abdominal cramps,
urinating, diarrhea, muscular tremors, staggering gait, pinpoint pupils, hypotension,
slow heartbeat, breathing difficulty, and possibly death, if not promptly treated by
a physician[84, 85].
4.2 Data preparation
The data preparation procedures I took in this chapter are similar to those in Chap-
ter 3. Examples of both classes, cholinesterase inhibitors (positive examples) and
compounds having no inhibitory effect on cholinesterase (negative examples) are
required to train a classification model. The information about cholinesterase in-
hibitors are scattered in numerous references. A total of 132 cholinesterase inhibitors
were manually collected from available literatures with the help of a few simple au-
tomated text retrieval programs. The text retrieval programs I use are a set of
in-house developed Perl programs that can automatically search PubMed database
with keyword query. Specifically, they include a NCBI interface, a text format-
ter, and a job planner. They are able to download relevant abstracts and modify
them to highlight certain keywords, such as “inhibitor”, “inhibitory”, “IC50”, and
“cholinesterase” etc. They also sort the retrieved abstracts by frequencies of key
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words of our interests in them. This small toolkit can improve the efficiency of in-
hibitors searching in literatures. However, the techniques underpinning them belong
to the IT field and thus beyond the scope of this thesis.
Then a total of 1588 negative examples (“non-” cholinesterase inhibitors) are
selected from the inhibitors of 1170 “negative proteins”. The source of “negative
proteins” is the therapeutic target databse (TTD)[23]. The composition of the
“negative proteins” encompasses major pharmacological important proteins, such
as enzymes, receptors, transporters, and antibodies et al. The 2D structures of
these compounds are downloaded from ChemIDplus2. Then to calculate the 159 de-
scriptors described in Chapter 2, the 2D structures are converted into 3D structures
using Concord 4.0.1.
In this process, the structures of the cholinesterase inhibitors and “non-” cholinesterase
inhibitors undergo a series of cleaning procedures: a) those whose nomenclature are
not standard and hence impossible to find their structures are firstly removed; b)
duplicates within each class are removed; c) compounds shared by both classes are
removed from negative class because the positive examples are confirmed in ref-
erences and the quality of positive data is believed to be better; d) counterions
and solvent molecules are removed, as well as obviously unsuitable compounds, e.g.
heavy metal containing compounds, compounds whose molecular weight below 150
or above 1000.
After the data cleaning step, a 159-dimensional data set is successfully generated
2ChemIDplus (http://chem.sis.nlm.nih.gov/chemidplus/) is a free, web-based search system
that provides access to structure and nomenclature authority files used for the identification of
chemical substances cited in National Library of Medicine (NLM) databases. ChemIDplus also
provides structure searching and direct links to many biomedical resources at NLM and on the
Internet for chemicals of interest. The database contains over 368,000 chemical records, of which
over 206,000 include chemical structures, and is searchable by Name, Synonym, CAS Registry
Number, Molecular Formula, Classification Code, Locator Code, and Structure.
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Figure 4.2: The number of principal components VS the percentage of total variance
they represent.
with 116 positive examples and 1405 negative examples. This data set is further
split into training and testing sets with the ratio of 8:2. Training data are used
to tune free parameters and train a classification model. Testing data are used to
measure and evaluate the performance of different classification models.







Training set 92 1125 1217
Testing set 24 280 304
Total No. 116 1405 1521
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Both the training data and test data undergo the preprocessing techniques—
normalization and PCA discussed in Chapter 2. Figure 4.2 shows the PCA analysis
of the training data. From it, we can see that without loss of any variances encoded
in the data set, 49 dimension redundant descriptors can be reduced. Keeping 99%
of the variances, 102 dimensions can be reduced. Keeping 90% of the variances, 133
dimensions can be reduced. To be consistent with the approach used in last chapter,
I construct new training and testing data sets with the first n principal components
while n = 26, n = 57, and n = 110.
4.3 Prediction results and analysis
After scaling and PCA preprocessing, we are ready to train classification models.
Different machine learning algorithms were explored on the four sets of training
data. Their performances are measured on the testing data sets. The results and
discussion are given in this section:
4.3.1 Decision tree prediction
The unpruned decision tree C4.5 generated for original data is shown in Figure 4.3.
Its interpretation method is identical to that of section 3.3. The threshold values
used in this decision tree are the same as those after scaling.
This time, the decision tree is more complicated. It has a maximal depth of 15
layers, whereas the longest branch in the tree for 5-HT2 antagonist prediction is only
8 layers. 12 descripors, more than 1/3 of the descriptors tested in decision nodes
of this tree are also tested in the nodes of in the decision tree for 5-HT2 antagonist
prediction. But the remaining 2/3 of the descriptors, about 20 attributes, were never
used in the decision tree for 5-HT2 antagonist prediction.
Table 4.2 presents the final results on testing data sets. The precision, recall, F
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Figure 4.3: The decision tree generated for cholinesterase inhibitors
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Table 4.2: Summary of the decision tree’s performance on original and PCA pre-
processed data sets
Measurement On original data
On the data sets after PCA
110-dimension 57-dimension 26-dimension
Precision 78.95% 93.75% 71.43% 76.92%
Recall/Sensitivity 62.50% 62.50% 41.67% 41.67%
F measure 69.77% 70.00% 52.62% 54.06%
Specificity 98.57% 99.64% 98.57% 98.93%
measure, sensitivity and specificity are compared on the four data sets. From it, we
can see that the 57-dimension PCs data set and 26-dimension PCs data set do not
give a satisfactory results. The recall value (or sensitivity) is less than 50%, which
means the prediction is worse than random guesswork for positive examples. The
results on 110-dimension PCs data set is the best among the four group of results
and slightly better than those on original data set. The number of true positive,
false negative, true negative and false positive are 15, 9, 279 and 1 respectively for
110-dimension PCs data set whereas 15, 9, 276 and 4 respectively for original data
set. Thus recall and sensitivity does not increase. However, with the improvement
on negative data prediction, the specificity increased about 1%, from 98.47% to
99.64%. More importantly, with the decrease of false negatives, the specificity on
the data set consisting of 110 principal components is 15% higher than the specificity
on original data set.
These results confirmed the idea brought up in last chapter that the descriptors
are highly correlated. 57 principal components are able to represent 99% of the
original variances and 110 principal components are able to represent the original
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data without any loss of information. Also, the information needed for classification
does not necessarily reside in directions with big variances. The addition of the last
1% of the variance lead to 18% of improvement to the F measure.
4.3.2 K-Near Neighbor prediction
As there are 1217 examples in training data set, the parameter k used in knn is
scanned in the range of 1, 2, . . . , 34, which is approximately the square root of 1217.
Such a big range ensures that the optimal value for the parameter of k. The experi-
ments in previous chapter indicates that Fmeasure gives a more objective measure-
ment for unbalanced data sets than Precision, Recall, Sensitivity and Specificity.
Hence in order to find the optimal k, Fmeasure is plotted against k. Figure 4.4
illustrates the parameter tuning process. From it, we can see the best Fmeasure
on the original training data, 110-dimension PCs training data, 57-dimension PCs
training data and 26-dimension PCs training data are 55.48%, 55.48%, 54.90% and
59.63% respectively. The results are the average values on 10-fold cross-validation
training data set. The maximal Fmeasure are reached when k is set to 3, 3, 3 and
4 respectively.
The classification capability are consequently measured on testing data sets with
their optimal k values (shown in Table 4.3). From it, we can see that:
• As the decision tree method, K nearest neighbor gives better prediction on
negative data than on positive data. The specificity values are about 30%
higher than sensitivity (Recall) values. Previous prediction of 5-HT2 antago-
nist shows the same trend. Cai et al reported the same phenomenon in protein
function predictions[59, 60]. This is mainly due to the shortage of positive ex-
amples.
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Figure 4.4: The knn parameter tuning process based on 10-fold cross validation
Table 4.3: Summary of the knn’s performance on original and PCA preprocessed
testing sets
Measurement On original data
On the data sets after PCA
110-dimension 57-dimension 26-dimension
Precision 89.47% 89.74% 85.00% 80.00%
Recall/Sensitivity 70.83% 70.83% 70.83% 66.67%
F measure 79.07% 79.07% 77.27% 72.73%
Specificity 99.29% 99.29% 98.57% 98.57%
• Original data set and 110-dimension PCs data set (keeping the 100% variances
in original data), give exactly the same results. 57-dimension PCs data set
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(keeping the 99% variances in original data) gives results inferior to that from
the former two and 26-dimension PCs data set (keeping the 90% variances in
original data) gives results inferior to that from 57-dimension PCs data set.
Such results are consistent with previous experiments.
• K nearest neighbor gives better results than decision tree does on cholinesterase
inhibitor prediction. The difference between two groups of results are larger
than that of 5-HT2 antagonist prediction. In case of original data set and 110-
dimension PCs data set, Fmeasure and Sensitivity (or Recall) are improved
by about 8% and 9% respectively.
4.3.3 SVM prediction
SVMs are trained with the kernel parameter σ scanned in the range of [0, . . . , 8]
with an interval of 0.2. After σ = 8, the Fmeasure becomes stable and does not
change much with increasing σ. Figure 4.5 gives the plot of Fmeasure against σ
for the four training sets. The best σ found are 7, 7, 0.4 and 0.2, corresponding to
the optimal Fmeasure values: 60.24%, 60.24%, 54.78%, and 54.12% respectively.
Afterward the classification performances are measured on four testing sets with
their optimal σ values. Table 4.4 gives the summary. Among all the three ap-
proaches, SVM produces the best results. The best Fmeasure is as high as 89.36%
on original data set and 110-dimension PCs data set. By contrast, decision tree only
gives the highest Fmeasure of 70.00% and knn 79.07%. Furthermore, it is found
that the achievement of SVM is mainly contributed by the improvement of Sen-
sitivity (Recall) values, or in other words, the prediction improvement on positive
examples. Among 24 true positive examples, SVM is able to pick out 21 examples
correctly. This is amazingly high.
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Figure 4.5: The SVM parameter tuning process based on 10-fold cross validation
Table 4.4: Summary of the SVM’s performance on original and PCA preprocessed
testing sets
Measurement On original data
On the data sets after PCA
110-dimension 57-dimension 26-dimension
Precision 91.30% 91.30% 94.12% 94.44%
Recall/Sensitivity 87.50% 87.50% 66.67% 70.83%
F measure 89.36% 89.36% 78.05% 80.95%
Specificity 99.29% 99.29% 99.64% 99.64%
4.4 Summary
In this chapter, we use decision tree, knn and SVM to predict the inhibitory effects
of different compounds on the enzyme target–cholinesterase. Cholinesterase is the
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enzyme responsible for the rapid hydrolysis of the neurotransmitter–acetylcholine.
Cholinesterase inhibitors, also called anticholinesterase agents, block the catalysis of
cholinesterase. Consequently acetylcholine is accumulated at the receptor and causes
more intensive and prolonged cholinergic activation. This effect can be desirable
in the case of treatment of glaucoma, myasthenia gravis, and Alzheimer’s disease.
This effect, if too strong, can also lead to toxicity, in the case of insecticides and
chemical warfare agent. Therefore extra caution should be paid when designing new
cholinesterase inhibitors for medications.
The procedure begins with the search of cholinesterase inhibitors and non-cholinesterase-
inhibitor chemicals. A total of 92 cholinesterase inhibitors and 1125 non-cholinesterase-
inhibitor representatives are collected to train different classification models. Then
24 unseen cholinesterase inhibitors and 280 non-cholinesterase-inhibitor chemicals
are used to test the different models. In order to train a good model, other pre-
processing techniques, such as normalization and principal components analysis are
used.
From the algorithmic evaluation perspective, the results obtained in this chapter
are similar to that of 5-HT2 antagonist prediction.
SVM outperforms decision tree and knn. The best Fmeasure achieved by SVM
is 89.36%, which corresponds to a precision value of 91.30% and a recall value of
87.5%. This Fmeasure is 19.59% higher than that of decision tree, and 10.29%
higher than that of knn.
110-dimension PCs data set that keeps the 100% variances in the training data
set, gives exactly the same good results as the original data set in the case of knn
and SVM, and slightly better results than the original data set in case of decision
tree. This once again confirmed that PCA is useful in dimensionality reduction.
Chapter 5
Inhibitor prediction for the ADME
associated protein– CYP3A4
Although the speed of lead compound screening has been increased greatly during
the early stages of drug discovery, rapid optimization of parameters that determine
whether a potent inhibitor will become a successful drug remains a challenge in
improving the efficiency of the drug discovery process. The speed with which drugs
are screened for properties such as absorption, cytochrome P450 (CYP) inhibition,
and metabolic stability is still several orders of magnitude lower than those for high-
throughput methods used in lead identification. Parameters that define absorption,
distribution, metabolism, and excretion properties of drug candidates are essential
for therapeutic efficacy, and thus should be optimized during early stages of drug
discovery.
In this chapter, machine learning techniques are tested for their applicability to
expedite identifying drug candidates with potential to inhibit cytochrome P4503A4
. This is important in the drug discovery process because metabolism by CYP
represents an important clearance mechanism for the vast majority of drugs, thus





Metabolic transformation of drug molecules represents a key process by which drugs
are cleared from the body. Metabolic transformations have traditionally been di-
vided into two phases. Phase I reactions (biotransformation) include oxidation,
reduction, and hydrolysis which primarily serve to increase the hydrophilicity and
enhance the excretion of a drug by unveiling or incorporating a polar functional
group into the molecule (-OH, -SH, -NH2, or -COOH). Phase II reactions (conjuga-
tion) further increase the polarity of a drug by modifying a functional group to form
O- or N-glucuronides, sulfate esters, α-carboxyamides, and glutathionyl adducts.
Metabolic stability is one of several major concerns in defining the oral bioavail-
ability and systemic clearance of a drug. After a drug is administered orally, it
first encounters metabolic enzymes in the gastrointestinal lumen and the intestinal
epithelium. After it is absorbed into the bloodstream through the intestinal epithe-
lium, it is delivered to the liver via the portal vein. A drug can be effectively cleared
by intestinal or hepatic metabolism before it reaches systemic circulation, a process
known as first-pass metabolism. The stability of a compound toward metabolism
within the liver as well as extrahepatic tissues will ultimately determine the con-
centration of the drug found in the systemic circulation and affect its half-life and
residence time within the body.
5.1.2 Cytochrome P450s
The cytochrome P450s (CYP) are a superfamily of enzymes which are found in
all forms of living organism. They are responsible for the metabolism of many
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endogenous compounds, participate in the activation/deactivation of many carcino-
gens and detoxify many xenobiotics. In particular, in human body they metabolize
many drugs and hence are of great interest to pharmacologists and toxicologists.
The cytochrome P450 mixed function monooxygenases are located on the smooth
endoplasmic reticulum of cells throughout the body, but the highest concentrations
are found in the liver (hepatocytes) and small intestine[86]. These enzymes are
responsible for the oxidative (Phase I) metabolism of a large number of compounds,
including many medications. They biotransform lipophilic drugs to more polar
compounds that can be excreted by the kidneys[87]. The metabolites are usually less
active than the parent compound, although some drugs undergo biotransformation
to become pharmacologic active agents. In some cases the metabolites can be toxic,
carcinogenic or teratogenic[87].
At least 12 cytochrome P-450 gene families have been identified in humans,
although only 3 families are involved in the majority of the drug biotransformations;
they are the cytochrome P-450 1, 2 and 3 (CYP1, CYP2 and CYP3). A single
hepatocyte can contain a variety of cytochrome P-450 enzymes. An individual
enzyme of cytochrome P-450 may be able to metabolize many different drugs, but
a given drug may be primarily metabolized by a single enzyme[87].
Members of the CYP3A subfamily are the most abundant cytochrome enzymes
in human, accounting for 30% of the cytochrome enzymes in the liver and 70% of
those in the gut. CYP3A4 is the major form of cytochrome P-450 in the adult liver
and metabolizes the greatest proportions of drugs[87]. This enzyme and CYP3A3,
which are 97% identical and cannot be distinguished from each other based on the
substrates that they metabolize, are the major enzymes expressed in the small in-
testine, while CYP3A5 is the major enzyme expressed in the stomach[88]. CYP3A5
is present in only 20% ∼ 30% of Caucasians, but being deficient in CYP3A5 poses
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no problem because the CYP3A4 enzyme is available to assume its functions[89].
5.1.3 CYP3A4 metabolism-based drug interactions
Metabolic stability of a drug is a major factor that will ultimately determine the
concentration of the drug found in the systemic circulation. It is quite common
for two or more drugs to be co-administered to a patient to increase the chances
for a drug-drug interaction to occur. Many drug-drug interactions are metabolism-
based and result from two or more drugs competing for the same enzyme, with the
majority of these interactions involving CYP[90, 92]. For example, if a new chemical
entity is a potent cytochrome P450 inhibitor, it may inhibit the metabolism of a co-
administered medication. Thus, much higher plasma concentrations of the second
drug are attained. For a drug with a narrow therapeutic index, this would lead to
an adverse reaction. This problem has prompted the need to assess drug safety early
during drug discovery/development, and to identify and eliminate compounds that
may exhibit a potential for undesirable drug interactions. Assessing the safety of
new drug candidates during drug discovery can save considerable amount of time
and money, and prevent the exposure of patients to unnecessary risk, especially if a
drug must later be removed from the market because of safety issues[91].
As the most abundantly expressed CYP isoform, CYP3A4 is responsible for the
metabolism of more than 50% of pharmaceuticals[92, 93, 94]. As a consequence many
important drug-drug interactions observed in the clinic are associated with drugs
which are principally metabolized by CYP3A4. The two major reasons for drug-
drug interactions involving CYP3A4 are induction and inhibition, with inhibition
appearing to be the more important in terms of known clinical problems.
As a means of avoiding disasters in vivo drug interactions, the FDA requires
identification of the specific metabolic pathways from which potential inhibition or
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induction interactions may be inferred and, most recently, the effect of the new drug
on hepatic P450. As a consequence, many pharmaceutical companies employ in vitro
drug-drug assays early in drug discovery to predict potential interactions of new
drug candidates in an attempt to minimize undesirable characteristics associated
with novel compounds. Many articles have been published over the past several
years outlining the advances in high-throughput CYP inhibition screens.
5.2 Data preparation







Training set 140 1180 1320
Testing set 37 318 355
Total No. 177 1498 1675
In this chapter, we mainly focus on the inhibitor prediction of the most important
representative of the CYP family—CYP3A4. In order to build machine learning
models, 194 CYP3A4 inhibitors are first collected from available literature from
PubMed. Then a total of 1795 negative examples (non-CYP3A4-inhibitor chemicals)
are selected from the inhibitors of a group of “negative proteins”. The method
of defining negative proteins is adopted from C.Z. Cai et al[60]. Specifically these
negative proteins are selected from seed proteins of the curated protein families in the
Pfam database1. Those seed proteins known to not belong to the family of CYP3A4
1Pfam (http://www.sanger.ac.uk/Software/Pfam/) is a large collection of multiple sequence
alignments and hidden Markov models covering many common protein domains and families.
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Figure 5.1: The number of principal components VS the percentage of total variance
they represent.
(EC 1.14) are used as negative proteins. Negative protein representatives include
proteins in all protein families other than EC 1.14. After collecting the positive
and negative examples, the 3D structures of the inhibitors and non-inhibitors are
generated by Concord based on their 2D structures.
After going through the same data purification procedures as described in Section
3.2, a 159-dimensional data set is successfully generated with 177 positive examples
and 1498 negative examples. This data set is further split into training and test-
ing sets. After scaling and PCA preprocessing, it is ready to construct different
classification models.
Figure 5.1 shows the principal component analysis results of the training data.
From it, we can see that without loss of any variances encoded in the data set, we
can remove 47 dimension redundant descriptors. Keeping 99% of the variances, 103
dimensions can be removed. Keeping 90% of the variances, 133 dimensions can be
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removed. In consistence with the approach used in previous chapters, I choose to
build new training and testing data sets with the first n principal components while
n = 26, n = 56, and n = 112.
5.3 Prediction results and analysis
The original data set and the PCA processed data sets consisting of the first 112, 56
and 26 principal components are analyzed by different machine learning approaches.
The results are presented as follows.
5.3.1 Decision tree prediction
Table 5.2: The most frequently used descriptors
No. Name Description
6 NF Count of F atoms
12 NS Count of S atoms
17 Ndonr Number of H-bond donors
27 5χCH Simple molecular connectivity Chi indices for cycles of 5 atoms
75 S(25) Atom-type Estate sum for =C<
86 S(36) Atom-type Estate sum for >N-
106 S(56) Atom-type Estate sum for -S-
134 q+ Atomic charge on the most positively charged H atom
136 µ Molecular dipole moment
The unpruned decision tree C4.5 generated for the original data is shown in
Figure 5.2. This chart follows the convention described in section 3.3. A prominent
characteristic of the tree is that it is much more complicated, compared to the
decision trees from previous two chapters. It has 76 nodes and 20 layers of branches
at most, while the tree generated for cholinesterase inhibitors has 43 nodes and 15
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Figure 5.2: The decision tree generated for cholinesterase inhibitors
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Figure 5.3: The decision tree generated for cholinesterase inhibitors(Continued)
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layers of branches and the tree for 5-HT2 antagonist has only 37 nodes and 8 layers.
Table 5.3: Summary of frequently used descriptors
Descriptors used twice (24 in total)
2 (A, C) 4 (A, C) 7 (A, C) 13 (B, C) 14 (A, C) 16 (B, C)
25 (B, C) 48 (A, C) 49 (A, B) 55 (B, C) 59 (B, C) 60 (B, C)
62 (A, C) 63 (B, C) 64 (A, C) 68 (A, C) 70 (B, C) 74 (B, C)
87 (B, C) 132 (A, C) 133 (A, B) 135 (A, B) 138 (A, C) 154 (B, C)
Descriptors used once (38 in total)
1 (C) 3 (C) 11 (C) 15 (C) 20 (B) 22 (C)
23 (C) 24 (B) 26 (C) 29 (A) 37 (C) 41 (B)
44 (C) 47 (A) 52 (C) 56 (B) 58 (C) 72 (C)
76 (C) 77 (C) 80 (B) 84 (B) 85 (B) 88 (C)
89 (A) 90 (C) 91 (A) 92 (B) 93 (A) 104 (C)
137 (C) 141 (C) 147 (A) 148 (A) 152 (C) 153 (A)
154 (C) 158 (C)
Table 5.4: Summary of the decision tree’s performance on original and PCA pre-
processed data sets
Measurement On original data
On the data sets after PCA
112-dimension 56-dimension 26-dimension
Precision 45.16% 48.28% 46.43% 62.50%
Recall/Sensitivity 37.84% 37.84% 35.14% 13.51%
F measure 41.18% 42.43% 40.00% 22.22%
Specificity 94.65% 95.28% 95.28% 99.06%
A further analysis of the descriptors shows that the decision tree for CYP3A4
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inhibitors uses 53 descriptors, the tree for cholinesterase inhibitors uses 32 descrip-
tors, and the tree for 5-HT2 antagonist uses 30 descriptors. There are 9 common
descriptors used by all the three decision trees. Table 5.2 gives the summary list.
There are 24 descriptors appeared twice and 38 descriptors appeared once in the
three decision trees. Due to the space limitation, only their serial numbers are listed
in Table 5.3. The letter in the bracket tells where the descriptor appears. “A” stands
for 5-HT2 antagonist prediction, “B” stands for cholinesterase inhibitor prediction
and “C”, for CYP3A4 inhibitor prediction.
Nonetheless, the complexity compromises the generalization capability of the
tree, which is illustrated by the prediction on the unseen testing data set. In table
5.4, the summary of the results on testing data sets is presented. The precision,
recall, F measure, sensitivity and specificity are compared on the four data sets.
From it, we can see that although the prediction for negative examples are very
high (the specificity values are all above 90%), this complex decision tree could not
give an acceptable prediction accuracy for positive examples, which are our main
focus. The recall / sensitivity value are only 37.84%, 37.84%, 35.14% and 13.51% for
the original data set, the 112-dimension PCs data set, the 56-dimension PCs data
set, and the 26-dimension PCs data set respectively. This means among 37 positive
examples in the testing data set, only 14, 14, 13 and 5 are predicted correctly for
the four data sets.
The poor performance on positive examples may be explained by the dramatic
increase of the complexicity in the training data. The positive class and negative
class probably overlapped a lot in the input space. The following knn and SVM
prediction prove this idea.
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Figure 5.4: The knn parameter tuning process based on 10-fold cross validation
5.3.2 K-Near Neighbor prediction
During training, the number of how many nearest neighbors to use, denoted by
k is scanned in the range of 1, 2, . . . , 36. 36 is calculated as the square root of
approximately 1320, the number of training examples. Figure 5.4 gives the plot of
Fmeasure against k. From it, we can see that the overall trend is that the bigger the
k value, the smaller the Fmeasure. The maximum Fmeasure are reached when k is
set to 1 in all the four cases. The best Fmeasure on the original data, 112-dimension
PCs data, 56-dimension PCs data and 26-dimension PCs data are 32.92%, 32.92%,
33.20% and 31.08% respectively.
Finally the classification results are measured on testing data sets with their
optimal k values (See Table 5.5). Obviously knn gives better overall prediction than
decision tree. The improvement for positive data are most obvious. On original
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Table 5.5: Summary of the knn’s performance on original and PCA preprocessed
testing sets
Measurement On original data
On the data sets after PCA
112-dimension 56-dimension 26-dimension
Precision 84.00% 84.00% 83.33% 75.00%
Recall/Sensitivity 56.76% 56.76% 54.05% 56.76%
F measure 67.74% 67.74% 65.57% 64.00%
Specificity 98.74% 98.74% 98.74% 97.80%
data set and 112-dimension PCs data set, the Sensitivity (Recall) value increased
by about 20%, on 56-dimension and 26-dimension PCs data sets, increased even
more. But due to the shortage of positive data, their prediction is still much worse
than that of negative data. The Specificity values are all around 98%, more than
40% higher than the Sensitivity values. This applies to the decision tree prediction
too. But different from the previous experiments, all the four data sets give similar
results this time. The original data set and 112-dimension PCs data give exactly
the same performance, slightly higher measurements than the other two data sets.
5.3.3 SVM prediction
SVMs are trained with the kernel parameter σ scanned in the range of [1, . . . , 150]
with an interval of 2. Such a large range is scanned because this time for three data
sets of four, the Fmeasure shows a dramatic increase trend with respect to σ in the
range of [0, . . . , 8], but as σ gets larger, the performances gradually become stable
with only a small fluctuation. Only a large scan range of σ can give a whole picture
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Figure 5.5: The SVM parameter tuning process based on 10-fold cross validation
of the trend. Fmeasure are plotted against σ for the four training sets in Figure 5.5.
The best σ found are 33, 15, 4 and 1 respectively. The classification performance
are measured on four testing sets with their optimal σ values. Table 5.6 gives the
summary.
Such result is inferior to its counterparts presented in Chapter 3 and Chapter
4. As far as Fmeasure is concerned, the best Fmeasure for CYP3A4 data set
is about 10% less than that of cholinesterase, and more than 12% less than that
of 5HT2 (See Figure 5.6). And the best Recall (Sensitivity) also decrease 8% and
10% respectively, compared with that of 5HT2 and cholinesterase. The best mea-
surements are achieved on original data set, then on 112-dimension PCs data set,
56-dimension PCs data set and 26-dimension PCs data set. This demonstrates that
the CYP3A4 data set is really more complicated. Simple methods like decision tree
and PCA do not work well on it.
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Table 5.6: Summary of the SVM’s performance on original and PCA preprocessed
testing sets
Measurement On original data
On the data sets after PCA
112-dimension 56-dimension 26-dimension
Precision 82.86% 83.87% 75.00% 79.17%
Recall/Sensitivity 78.38% 70.27% 64.86% 51.35%
F measure 80.81% 76.47% 69.56% 62.30%
Specificity 98.11% 98.43% 97.48% 98.43%
Figure 5.6: SVM results comparison on 3 data sets (Blue — 5HT2; Orange —
Cholinesterase; Yellow — CYP3A4)
5.4 Summary
CYP3A4 is an important enzyme responsible for metabolism of more than 50% of
oral drugs. In this chapter, decision tree, knn and SVM are applied to analyze the
potential of a compound to inhibit CYP3A4.
Results show that the prediction for CYP3A4 inhibitors is not as good as that
of 5-HT2 and cholinesterase. The decision tree does not work in this case. Its
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prediction accuracy for positive data cannot reach 50%, which is less than random
guesswork. knn and SVM give just acceptable results. The best Fmeasure are
67.74% and 80.81% respectively. PCA does not work well neither. 112-dimension
PCs data which keeps 100% variance of information fail to give the same results as
the original data set.
Possible reason is that CYP3A4 is a very broad functional enzyme. It can me-
tabolize more than 50% of the oral pharmaceuticals. Therefore it is very possible
that there are some examples in the negative sample data, which can interact with
CYP3A4 as its substrates. On the other hand, its inhibitors may lack specificity in
structures. Or it is very difficult to tell CPY3A4 inhibitors from its substrates.
So far, we have finished the main work in the thesis. Three inhibitor/antagonist
prediction problems are explored for different proteins of different biological signif-
icance. Conclusion and reflections are made in next chapter on the basis of the
results we have got in Chapter 3, 4 and 5.
Chapter 6
Conclusion and future work
The drug discovery process has evolved over the past 60 years from serendipitous
findings of biologically active natural products, to rational design of potent and selec-
tive pharmacologically active compounds based on elucidation of three-dimensional
structure of target proteins, to high-throughput screening against cloned and ex-
pressed enzymes and receptors, and to the construction of enormously diverse com-
binatorial libraries for ultra high-throughput screening.
However, even with rapid and efficient technologies to identify drug leads, it
takes several years, in some cases up to 15 years, to bring a drug from discovery to
market with an estimated price of US$880 million per individual drug. These high
costs cannot be solely attributed to inflation or extensive clinical testing required
by federal agencies; they also reflect the high rate of failure in the preclinical and
clinical development of drugs. The ultimate success of a compound is defined not
only by its biological activity and potency, but also by its ADME/toxicity related
properties.
In this work, three machine learning methods, namely decision tree, k-nearest
neighbor and support vector machine and preprocessing techniques such as normal-
ization and principal component analysis were explored for potential application in
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Figure 6.1: Fmeasure comparison on original data sets
drug lead identification and its ADME/toxicity analysis. Specifically, these machine
learning methods were investigated to predict the inhibitors/antagonists for the re-
ceptor target—5-HT2, the enzyme target—cholinesterase and the ADME related
target—CYP3A4. The following results were obtained:
• Figure 6.1 shows the comparison among different machine learning approaches
using Fmeasure on original data sets (PCA preprocessed data sets give sim-
ilar results and therefore the figure is omitted). Fmeasure balances between
how many positive examples are recognized and how many examples are true
positive among those predicted positive ones. Thus it works as an effective
indicator when tuning the free parameters in knn and SVM, as well as an ob-
jective measurement for the capability of each classification model. It can be
concluded that in this application, SVM always outperforms knn and decision
tree. In the case of 5-HT2 antagonist prediction, SVM gives Fmeasure of
92.31% whilst knn gives Fmeasure of 83.33% and decision tree, only 78.95%.
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The difference becomes even bigger for cholinesterase and CYP3A4 inhibitor
prediction.
• Simple models give better prediction than complex models. A good example
is the decision trees generated for 5-HT2 antagonist, cholinesterase inhibitor
and CYP3A4 inhibitor prediction. On the original data sets, the decision tree
generated for 5-HT2 antagonist has 37 nodes in total and 8 layers of branches
at most; the tree for cholinesterase inhibitor has 43 nodes and 15 layers of
branches at most; and the tree for CYP3A4 inhibitor has 76 nodes and 20
layers of branches at most. By contrast, the Fmeasure for 5-HT2 antagonist,
cholinesterase inhibitor and CYP3A4 inhibitor prediction are 78.95%, 69.77%
and 41.18% respectively, in a dramatic decreasing trend. The knn and SVM
predictions show the same trend too (See Figure 6.1). On the one hand, this
phenomenon once again confirmed the Ockham’s razaor theorem. On the other
hand, this may reflect the different complexities and quality within the three
data sets.
• With the exception of SVM prediction on CYP3A4 inhibitors, most PCA
preprocessed data sets with 100% variances give the same, or slightly better
results as the original data sets. These results are also the best among the
original data set, PCA data set with 100%, 99% and 90% variances. This
demonstrates that PCA is helpful to reduce the dimension of the data sets and
speed up the CPU computation without compromising in the performance.
This also gives us a hint that the descriptors we have used are capable of
catching the necessary characteristics of thousands of compounds with regard
to inhibitor classification. But there may be certain degree of redundancy.
Around 46∼50 descriptors can be removed without losing any variances in the
original data. Of course, in order to further improve the prediction accuracy,
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new descriptors which can describe and distinguish compounds from a different
perspective may be introduced.
• For the three inhibitor prediction problems, all the three machine learning
approaches give significantly better prediction on negative examples than on
positive examples. This may be due to the fact that the number of negative
examples is more than ten times that of positive examples. That is the negative
examples might represent a more comprehensive sample in the input space and
provide more useful information about its classification.
In order to improve the prediction performance of positive examples, more
positive examples in training data sets are desirable which can cover more
space in the input space. If equal numbers of positive and negative examples
of equal quality are given in the training data set, the difference between the
prediction accuracy on the two classes would become much smaller. This is
determined by the nature of machine learning algorithms. Currently almost
all the machine learning methods for two-class classification problems assume
that both of the two classes are well studied and equally distributed in the
hyper space. Therefore, unbalanced training data set will result in a classifier
that is better trained for one class over the other class.
In addition to adding more examples to balance the training set, new algo-
rithms are expected which can give different consideration to different classes
in very unbalanced data sets, like our cases in which the positive examples are
more than ten times that of negative examples.
The results obtained are quite exciting, which illuminate a novel approach to-
wards drug lead identification and toxicity/ADME analysis at early stage. However,
the methods adopted in this work are far from perfect. Further study is needed to
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deepen our understanding of the different chains in the machine learning screening
pipeline. Several directions are worth of our further exploration, such as:
• Feature selection
Using all the available descriptors to build statistical models may not be help-
ful, as the inclusion of irrelevant descriptors can cause the classical problem
of the “curse of dimensionality”[95], which leads to expensive computation
and compromised generalization performance. The selection of a good set of
features is an essential prerequisite in the design of an accurate predictive
model.
From the PCA analysis in this work, it is noted that there is certain redun-
dancy in the 159 QSAR descriptors used. For example, the first descriptor
“molecular weight” can be calculated linearly from the value of count of hy-
drogen atoms, halogen atoms, . . ., which correspond to the 2nd to 14th descrip-
tors. Besides, the 111th to 125th descriptors describe the electrotopological
state (E state) for the elements of Germanium (Ge), Arsenic (As) and Sele-
nium (Se), which are seldom shown in drug compounds. Therefore these kind
of descriptors give little useful information in the application of drug lead pre-
diction. In order to improve the performance of these machine learning models,
further work are needed to select a set of more informative descriptors, which
requires strong knowledge in chemistry and QSAR.
• SVM regression
In this work, the SVM classification method has been successfully applied to
inhibitor prediction. But, in essence, protein-ligand binding is not a simple
binary classification problem. Different inhibitors may have different binding
affinity. Chemical and biological experiments have provided some quantitative
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data regarding the binding affinity of various compounds to a particular pro-
tein, such as effective concentration 50% (EC50 value)1, which reveal valuable
information to us. Once this kind of information is available, SVM regression
may be a more powerful tool to analyze quantitatively the potential of a com-
pound to become an inhibitor of a particular protein. Song M. H et al[96] has
reported to use SVM regression in protein retention time prediction.
• Rule extraction
A limitation of SVM is that it generates black-box-like models, which are not
interpretable to medicinal chemists. Haydemar et al has reported a “proto-
type” based method to derive “if–then” rules from SVM models[97]. Another
possible approach to look into the black box might be training a decision tree
that mimics the behavior of SVM.
After solving these problems, an expert system to facilitate the decision mak-
ing of the pharmaceutical industry during lead discovery can be built in the fu-
ture. Currently most machine learning scientists only focus on how to improve the
performance of algorithms based on measurements of recall/sensitivity and preci-
sion/specificity et al, without any consideration of the particular field in which an
application lies. The ultimate goal of drug design software should be to find an
optimal experimental design during the lead discovery period, in order to maximize
pharmaceutical companies’ profit with lowest risk. Therefore, the profit and risk
analysis should be taken into consideration during model building. That is, the pre-
diction accuracy on both classes should be given different weights. Figure 6.2 gives
the flowchart of a simple expert system. Some operation research knowledge should
1The EC50 is commonly defined as the drug concentration at which the response has decreased
(increased) to 50% of the initial response, assuming that the response is a decreasing (increasing)
function of drug concentrate.
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Figure 6.2: Blueprint for an expert system to facilitate the decision making of the
pharmaceutical industry during lead discovery.
be introduced to the final model selection step to get the most practical model.
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